Author: "D. Coza" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"D. Coza"' showing total 41 results

Start Over Author "D. Coza"

41 results on '"D. Coza"'

1. Birth seasonality of childhood central nervous system tumors: Analysis of primary data from 16 Southern-Eastern European population-based registries

Author: Karalexi, M.A. Dessypris, N. Georgakis, M.K. Ryzhov, A. Jakab, Z. Zborovskaya, A. Dimitrova, N. Zivkovic, S. Trojanowski, M. Sekerija, M. Antunes, L. Zagar, T. Eser, S. Bastos, J. Demetriou, A. Agius, D. Coza, D. Gheorghiu, R. Kantzanou, M. Ntzani, E.E. Petridou, E.T.
Abstract: Season of birth, a surrogate of seasonal variation of environmental exposures, has been associated with increased risk of several cancers. In the context of a Southern-Eastern Europe (SEE) consortium, we explored the potential association of birth seasonality with childhood (0–14 years) central nervous system (CNS) tumors. Primary CNS tumor cases (n = 6,014) were retrieved from 16 population-based SEE registries (1983–2015). Poisson regression and meta-analyses on birth season were performed in nine countries with available live birth data (n = 4,987). Subanalyses by birth month, age, gender and principal histology were also conducted. Children born during winter were at a slightly increased risk of developing a CNS tumor overall [incidence rate ratio (IRR): 1.06, 95% confidence intervals (CI): 0.99–1.14], and of embryonal histology specifically (IRR: 1.13, 95% CI: 1.01–1.27). The winter peak of embryonal tumors was higher among boys (IRR: 1.24, 95% CI: 1.05–1.46), especially during the first 4 years of life (IRR: 1.33, 95% CI: 1.03–1.71). In contrast, boys
Published: 2020

2. Trends in incidence of thick, thin and in situ melanoma in Europe

Author: Lidia Sacchetto, Anna Gavin, Harry Comber, Christine Bouchardy, Siri Larønningen, Jaume Galceran, E. Van Eycken, Roberto Zanetti, M-D Chirlaque, P. Broganelli, Vesna Zadnik, Sally Vernon, Laufey Tryggvadottir, Eileen Morgan, Alexander Katalinic, David H. Brewster, Stefano Rosso, Marieke W. Louwman, Monika Hackl, R. Tumino, D. Coza, Trude Eid Robsahm, and M-J Sanchez
Subjects: Male, Cancer Research, Skin Neoplasms, Time Factors, Databases, Factual, Population, World health, Lesion, 030207 dermatology & venereal diseases, 03 medical and health sciences, Age Distribution, 0302 clinical medicine, Thin lesions, medicine, Humans, Neoplasm Invasiveness, Registries, Mortality, Sex Distribution, education, Melanoma, ddc:613, education.field_of_study, business.industry, Incidence, Incidence (epidemiology), Middle Aged, medicine.disease, Annual Percent Change, Europe, Melanoma mortality trends, Oncology, Mortality data, 030220 oncology & carcinogenesis, Breslow, Female, Invasive Melanoma, medicine.symptom, Melanoma incidence trends, Thickness, business, Demography
Abstract: Background We analysed trends in incidence for in situ and invasive melanoma in some European countries during the period 1995–2012, stratifying for lesion thickness. Material and methods Individual anonymised data from population-based European cancer registries (CRs) were collected and combined in a common database, including information on age, sex, year of diagnosis, histological type, tumour location, behaviour (invasive, in situ) and lesion thickness. Mortality data were retrieved from the publicly available World Health Organization database. Results Our database covered a population of over 117 million inhabitants and included about 415,000 skin lesions, recorded by 18 European CRs (7 of them with national coverage). During the 1995–2012 period, we observed a statistically significant increase in incidence for both invasive (average annual percent change (AAPC) 4.0% men; 3.0% women) and in situ (AAPC 7.7% men; 6.2% women) cases. Discussion The increase in invasive lesions seemed mainly driven by thin melanomas (AAPC 10% men; 8.3% women). The incidence of thick melanomas also increased, although more slowly in recent years. Correction for lesions of unknown thickness enhanced the differences between thin and thick cases and flattened the trends. Incidence trends varied considerably across registries, but only Netherlands presented a marked increase above the boundaries of a funnel plot that weighted estimates by their precision. Mortality from invasive melanoma has continued to increase in Norway, Iceland (but only for elder people), the Netherlands and Slovenia.
Published: 2018
Full Text: View/download PDF

3. Global surveillance of trends in cancer survival 2000-14 (concord-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries

Author: Claudia Allemani, Tomohiro Matsuda, Veronica Di Carlo, Rhea Harewood, Melissa Matz, Maja Nikšić, Audrey Bonaventure, Mikhail Valkov, Christopher J Johnson, Jacques Estève, Olufemi J Ogunbiyi, Gulnar Azevedo e Silva, Wan-Qing Chen, Sultan Eser, Gerda Engholm, Charles A Stiller, Alain Monnereau, Ryan R Woods, Otto Visser, Gek Hsiang Lim, Joanne Aitken, Hannah K Weir, Michel P Coleman, S Bouzbid, M Hamdi-Chérif, Z Zaidi, K Meguenni, D Regagba, S Bayo, T Cheick Bougadari, S S Manraj, A Fabowale, O J Ogunbiyi, D Bradshaw, N I M Somdyala, I Kumcher, F Moreno, G H Calabrano, S B Espinola, B Carballo Quintero, R Fita, M C Diumenjo, W D Laspada, S G Ibañez, C A Lima, P C F De Souza, K Del Pino, C Laporte, M P Curado, J C de Oliveira, C L A Veneziano, D B Veneziano, M R D O Latorre, L F Tanaka, M S Rebelo, M O Santos, G Azevedo e Silva, J C Galaz, M Aparicio Aravena, J Sanhueza Monsalve, D A Herrmann, S Vargas, V M Herrera, C J Uribe, L E Bravo, L S Garcia, N E Arias-Ortiz, D Morantes, D M Jurado, M C Yépez Chamorro, S Delgado, M Ramirez, Y H Galán Alvarez, P Torres, F Martínez-Reyes, L Jaramillo, R Quinto, J, M Mendoza, P Cueva, J G Yépez, B Bhakkan, J Deloumeaux, C Joachim, J Macni, R Carrillo, J Shalkow Klincovstein, R Rivera Gomez, E Poquioma, G Tortolero-Luna, D Zavala, R Alonso, E Barrios, A Eckstrand, C Nikiforuk, R R Woods, G Noonan, D Turner, E Kumar, B Zhang, F R McCrate, S Ryan, M MacIntyre, N Saint-Jacques, D E Nishri, C A McClure, K A Vriends, S Kozie, H Stuart-Panko, T Freeman, J T George, J T Brockhouse, D K O'Brien, A Holt, L Almon, S Kwong, C Morris, R Rycroft, L Mueller, C E Phillips, H Brown, B Cromartie, A G Schwartz, F Vigneau, G M Levin, B Wohler, R Bayakly, K C Ward, S L Gomez, M McKinley, R Cress, M D Green, K Miyagi, C J Johnson, L P Ruppert, C F Lynch, B Huang, T C Tucker, D Deapen, L Liu, M C Hsieh, X C Wu, M Schwenn, S T Gershman, R C Knowlton, G Alverson, G E Copeland, S Bushhouse, D B Rogers, J Jackson-Thompson, D Lemons, H J Zimmerman, M Hood, J Roberts-Johnson, J R Rees, B Riddle, K S Pawlish, A Stroup, C Key, C Wiggins, A R Kahn, M J Schymura, S Radhakrishnan, C Rao, L K Giljahn, R M Slocumb, R E Espinoza, F Khan, K G Aird, T Beran, J J Rubertone, S J Slack, L Garcia, D L Rousseau, T A Janes, S M Schwartz, S W Bolick, D M Hurley, M A Whiteside, P Miller-Gianturco, M A Williams, K Herget, C Sweeney, A T Johnson, M B Keitheri Cheteri, P Migliore Santiago, S E Blankenship, S Farley, R Borchers, R Malicki, J R Espinoza, J Grandpre, H K Weir, R Wilson, B K Edwards, A Mariotto. Y Lei, N Wang, J S Chen, Y Zhou, Y T He, G H Song, X P Gu, D Mei, H J Mu, H M Ge, T H Wu, Y Y Li, D L Zhao, F Jin, J H Zhang, F D Zhu, Q Junhua, Y L Yang, C X Jiang, W Biao, J Wang, Q L Li, H Yi, X Zhou, J Dong, W Li, F X Fu, S Z Liu, J G Chen, J Zhu, Y H Li, Y Q Lu, M Fan, S Q Huang, G P Guo, H Zhaolai, K Wei, W Q Chen, H Zeng, A V Demetriou, W K Mang, K C Ngan, A C Kataki, M Krishnatreya, P A Jayalekshmi, P Sebastian, A Nandakumar, R Malekzadeh, G Roshandel, L Keinan-Boker, B G Silverman, H Ito, H Nakagawa, M Sato, F Tobori, I Nakata, N Teramoto, M Hattori, Y Kaizaki, F Moki, H Sugiyama, M Utada, M Nishimura, K Yoshida, K Kurosawa, Y Nemoto, H Narimatsu, M Sakaguchi, S Kanemura, M Naito, R Narisawa, I Miyashiro, K Nakata, S Sato, M Yoshii, I Oki, N Fukushima, A Shibata, K Iwasa, C Ono, T Matsuda, O Nimri, K W Jung, Y J Won, E Alawadhi, A Elbasmi, A Ab Manan, F Adam, E Sanjaajmats, U Tudev, C Ochir, A M Al Khater, M M El Mistiri, G H Lim, Y Y Teo, C J Chiang, W C Lee, R Buasom, S Sangrajrang, S Kamsaard, S Wiangnon, K Daoprasert, D Pongnikorn, A Leklob, S Sangkitipaiboon, S L Geater, H Sriplung, O Ceylan, I Kög, O Dirican, T Köse, T Gurbuz, F E Karaşahin, D Turhan, U Aktaş, Y Halat, S Eser, C I Yakut, M Altinisik, Y Cavusoglu, A Türkköylü, N Üçüncü, M Hackl, A A Zborovskaya, O V Aleinikova, K Henau, L Van Eycken, Z Valerianova, M R Yordanova, M Šekerija, L Dušek, M Zvolský, G Engholm, H Storm, K Innos, M Mägi, N Malila, K Seppä, J Jégu, M Velten, E Cornet, X Troussard, A M Bouvier, A V Guizard, V Bouvier, G Launoy, P Arveux, M Maynadié, M Mounier, A S Worono, M Daoulas, M Robaszkiewicz, J Clavel, S Goujon, B Lacour, I Baldi, C Pouchieu, B Amadeo, G Coureau, A Monnereau, S Orazio, P M Preux, F Rharbaoui, E Marrer, B Trétarre, M Colonna, P Delafosse, K Ligier, S Plouvier, A Cowppli-Bony, F Molinié, S Bara, O Ganry, B Lapôtre- Ledoux, P Grosclaude, N Bossard, Z Uhry, F Bray, M Piñeros, J Estève, R Stabenow, H Wilsdorf-Köhler, A Eberle, S Luttmann, I Löhden, A L Nennecke, J Kieschke, E Sirri, K Emrich, S R Zeissig, B Holleczek, N Eisemann, A Katalinic, R A Asquez, V Kumar, E Petridou, E J Ólafsdóttir, L Tryggvadóttir, K Clough-Gorr, P M Walsh, H Sundseth, G Mazzoleni, F Vittadello, E Coviello, F Cuccaro, R Galasso, G Sampietro, A Giacomin, M Magoni, A Ardizzone, A D'Argenzio, M Castaing, G Grosso, A M Lavecchia, A Sutera Sardo, G Gola, L Gatti, P Ricci, S Ferretti, D Serraino, A Zucchetto, M V Celesia, R A Filiberti, F Pannozzo, A Melcarne, F Quarta, A G Russo, G Carrozzi, C Cirilli, L Cavalieri d'Oro, M Rognoni, M Fusco, M F Vitale, M Usala, R Cusimano, W Mazzucco, M Michiara, P Sgargi, L Boschetti, E Borciani, P Seghini, M M Maule, F Merletti, R Tumino, P Mancuso, M Vicentini, T Cassetti, R Sassatelli, F Falcini, S Giorgetti, A L Caiazzo, R Cavallo, R Cesaraccio, D R Pirino, M L Contrino, F Tisano, A C Fanetti, S Maspero, S Carone, A Mincuzzi, G Candela, T Scuderi, M A Gentilini, S Pier, S Rosso, A Barchielli, A Caldarella, F Bianconi, F Stracci, P Contiero, G Tagliabue, M Rugge, M Zorzi, S Beggiato, A Brustolin, F Berrino, G Gatta, M Sant, C Buzzoni, L Mangone, R Capocaccia, R De Angelis, R Zanetti, A Maurina, S Pildava, N Lipunova, I Vincerževskienė, D Agius, N Calleja, S Siesling, O Visser, Larønningen, B Møller, A Dyzmann-Sroka, M Trojanowski, S Góźdź, R Mężyk, T Mierzwa, L Molong, J Rachtan, S Szewczyk, J Błaszczyk, K Kępska, B Kościańska, K Tarocińska, M Zwierko, K Drosik, K M Maksimowicz, E Purwin-Porowska, E Reca, J Wójcik-Tomaszewska, A Tukiendorf, M Grądalska-Lampart, A U Radziszewska, A Gos, M Talerczyk, M Wyborska, J A Didkowska, U Wojciechowska, M Bielska-Lasota, G Forjaz de Lacerda, R A Rego, J Bastos, M A Silva, L Antunes, J Laranja Pontes, A Mayer-da-Silva, A Miranda, L M Blaga, D Coza, Russia: M Y Valkov, L Gusenkova, O Lazarevich, O Prudnikova, D M Vjushkov, A G Egorova, A E Orlov, L A Kudyakov, L V Pikalova, J Adamcik, C Safaei Diba, M Primic-Žakelj, V Zadnik, N Larrañaga, A Lopez de Munain, A A Herrera, R Redondas, R Marcos-Gragera, M L Vilardell Gil, E Molina, M J Sánchez Perez, P Franch Sureda, M Ramos Montserrat, M D Chirlaque, C Navarro, E E Ardanaz, M M Guevara, R Fernández-Delgado, R Peris-Bonet, M Carulla, J Galceran, C Alberich, M Vicente-Raneda, S Khan, D Pettersson, P Dickman, I Avelina, K Staehelin, B Camey, C Bouchardy, R Schaar, H Frick, C Herrmann, J L Bulliard, M Maspoli-Conconi, C E Kuehni, S M Redmond, A Bordoni, L Ortelli, A Chiolero, I Konzelmann, K L Matthes, S Rohrmann, Broggio, J Rashbass, D Fitzpatrick, A Gavin, D I Clark, A J Deas, D W Huws, C White, C Allemani, A Bonaventure, M P Coleman, V Di Carlo, R Harewood, M Matz, L Montel, M Nikšić, B Rachet, A D Turculeț, R Stephens, C A Stiller, E Chalker, H Phung, R Walton, H You, S Guthridge, F Johnson, J Aitken, P Gordon, K D'Onise, K Priest, B C Stokes, A Venn, H Farrugia, V Thurs eld, J Dowlin, D Currow, J Hendrix, C Lewis, Tıp Fakültesi, Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Claudia Allemani, Tomohiro Matsuda, Veronica Di Carlo, Rhea Harewood, Melissa Matz, Maja Nikšić, Audrey Bonaventure, Mikhail Valkov, Christopher J Johnson, Jacques Estève, Olufemi J Ogunbiyi, Gulnar Azevedo e Silva, Wan-Qing Chen, Sultan Eser, Gerda Engholm, Charles A Stiller, Alain Monnereau, Ryan R Woods, Otto Visser, Gek Hsiang Lim, Joanne Aitken, Hannah K Weir, Michel P Coleman, S Bouzbid, M Hamdi-Chérif, Z Zaidi, K Meguenni, D Regagba, S Bayo, T Cheick Bougadari, S S Manraj, A Fabowale, O J Ogunbiyi, D Bradshaw, N I M Somdyala, I Kumcher, F Moreno, G H Calabrano, S B Espinola, B Carballo Quintero, R Fita, M C Diumenjo, W D Laspada, S G Ibañez, C A Lima, P C F De Souza, K Del Pino, C Laporte, M P Curado, J C de Oliveira, C L A Veneziano, D B Veneziano, M R D O Latorre, L F Tanaka, M S Rebelo, M O Santos, G Azevedo e Silva, J C Galaz, M Aparicio Aravena, J Sanhueza Monsalve, D A Herrmann, S Vargas, V M Herrera, C J Uribe, L E Bravo, L S Garcia, N E Arias-Ortiz, D Morantes, D M Jurado, M C Yépez Chamorro, S Delgado, M Ramirez, Y H Galán Alvarez, P Torres, F Martínez-Reyes, L Jaramillo, R Quinto, J, M Mendoza, P Cueva, J G Yépez, B Bhakkan, J Deloumeaux, C Joachim, J Macni, R Carrillo, J Shalkow Klincovstein, R Rivera Gomez, E Poquioma, G Tortolero-Luna, D Zavala, R Alonso, E Barrios, A Eckstrand, C Nikiforuk, R R Woods, G Noonan, D Turner, E Kumar, B Zhang, F R McCrate, S Ryan, M MacIntyre, N Saint-Jacques, D E Nishri, C A McClure, K A Vriends, S Kozie, H Stuart-Panko, T Freeman, J T George, J T Brockhouse, D K O'Brien, A Holt, L Almon, S Kwong, C Morris, R Rycroft, L Mueller, C E Phillips, H Brown, B Cromartie, A G Schwartz, F Vigneau, G M Levin, B Wohler, R Bayakly, K C Ward, S L Gomez, M McKinley, R Cress, M D Green, K Miyagi, C J Johnson, L P Ruppert, C F Lynch, B Huang, T C Tucker, D Deapen, L Liu, M C Hsieh, X C Wu, M Schwenn, S T Gershman, R C Knowlton, G Alverson, G E Copeland, S Bushhouse, D B Rogers, J Jackson-Thompson, D Lemons, H J Zimmerman, M Hood, J Roberts-Johnson, J R Rees, B Riddle, K S Pawlish, A Stroup, C Key, C Wiggins, A R Kahn, M J Schymura, S Radhakrishnan, C Rao, L K Giljahn, R M Slocumb, R E Espinoza, F Khan, K G Aird, T Beran, J J Rubertone, S J Slack, L Garcia, D L Rousseau, T A Janes, S M Schwartz, S W Bolick, D M Hurley, M A Whiteside, P Miller-Gianturco, M A Williams, K Herget, C Sweeney, A T Johnson, M B Keitheri Cheteri, P Migliore Santiago, S E Blankenship, S Farley, R Borchers, R Malicki, J R Espinoza, J Grandpre, H K Weir, R Wilson, B K Edwards, A Mariotto. Y Lei, N Wang, J S Chen, Y Zhou, Y T He, G H Song, X P Gu, D Mei, H J Mu, H M Ge, T H Wu, Y Y Li, D L Zhao, F Jin, J H Zhang, F D Zhu, Q Junhua, Y L Yang, C X Jiang, W Biao, J Wang, Q L Li, H Yi, X Zhou, J Dong, W Li, F X Fu, S Z Liu, J G Chen, J Zhu, Y H Li, Y Q Lu, M Fan, S Q Huang, G P Guo, H Zhaolai, K Wei, W Q Chen, H Zeng, A V Demetriou, W K Mang, K C Ngan, A C Kataki, M Krishnatreya, P A Jayalekshmi, P Sebastian, A Nandakumar, R Malekzadeh, G Roshandel, L Keinan-Boker, B G Silverman, H Ito, H Nakagawa, M Sato, F Tobori, I Nakata, N Teramoto, M Hattori, Y Kaizaki, F Moki, H Sugiyama, M Utada, M Nishimura, K Yoshida, K Kurosawa, Y Nemoto, H Narimatsu, M Sakaguchi, S Kanemura, M Naito, R Narisawa, I Miyashiro, K Nakata, S Sato, M Yoshii, I Oki, N Fukushima, A Shibata, K Iwasa, C Ono, T Matsuda, O Nimri, K W Jung, Y J Won, E Alawadhi, A Elbasmi, A Ab Manan, F Adam, E Sanjaajmats, U Tudev, C Ochir, A M Al Khater, M M El Mistiri, G H Lim, Y Y Teo, C J Chiang, W C Lee, R Buasom, S Sangrajrang, S Kamsaard, S Wiangnon, K Daoprasert, D Pongnikorn, A Leklob, S Sangkitipaiboon, S L Geater, H Sriplung, O Ceylan, I Kög, O Dirican, T Köse, T Gurbuz, F E Karaşahin, D Turhan, U Aktaş, Y Halat, S Eser, C I Yakut, M Altinisik, Y Cavusoglu, A Türkköylü, N Üçüncü, M Hackl, A A Zborovskaya, O V Aleinikova, K Henau, L Van Eycken, Z Valerianova, M R Yordanova, M Šekerija, L Dušek, M Zvolský, G Engholm, H Storm, K Innos, M Mägi, N Malila, K Seppä, J Jégu, M Velten, E Cornet, X Troussard, A M Bouvier, A V Guizard, V Bouvier, G Launoy, P Arveux, M Maynadié, M Mounier, A S Worono, M Daoulas, M Robaszkiewicz, J Clavel, S Goujon, B Lacour, I Baldi, C Pouchieu, B Amadeo, G Coureau, A Monnereau, S Orazio, P M Preux, F Rharbaoui, E Marrer, B Trétarre, M Colonna, P Delafosse, K Ligier, S Plouvier, A Cowppli-Bony, F Molinié, S Bara, O Ganry, B Lapôtre- Ledoux, P Grosclaude, N Bossard, Z Uhry, F Bray, M Piñeros, J Estève, R Stabenow, H Wilsdorf-Köhler, A Eberle, S Luttmann, I Löhden, A L Nennecke, J Kieschke, E Sirri, K Emrich, S R Zeissig, B Holleczek, N Eisemann, A Katalinic, R A Asquez, V Kumar, E Petridou, E J Ólafsdóttir, L Tryggvadóttir, K Clough-Gorr, P M Walsh, H Sundseth, G Mazzoleni, F Vittadello, E Coviello, F Cuccaro, R Galasso, G Sampietro, A Giacomin, M Magoni, A Ardizzone, A D'Argenzio, M Castaing, G Grosso, A M Lavecchia, A Sutera Sardo, G Gola, L Gatti, P Ricci, S Ferretti, D Serraino, A Zucchetto, M V Celesia, R A Filiberti, F Pannozzo, A Melcarne, F Quarta, A G Russo, G Carrozzi, C Cirilli, L Cavalieri d'Oro, M Rognoni, M Fusco, M F Vitale, M Usala, R Cusimano, W Mazzucco, M Michiara, P Sgargi, L Boschetti, E Borciani, P Seghini, M M Maule, F Merletti, R Tumino, P Mancuso, M Vicentini, T Cassetti, R Sassatelli, F Falcini, S Giorgetti, A L Caiazzo, R Cavallo, R Cesaraccio, D R Pirino, M L Contrino, F Tisano, A C Fanetti, S Maspero, S Carone, A Mincuzzi, G Candela, T Scuderi, M A Gentilini, S Pier, S Rosso, A Barchielli, A Caldarella, F Bianconi, F Stracci, P Contiero, G Tagliabue, M Rugge, M Zorzi, S Beggiato, A Brustolin, F Berrino, G Gatta, M Sant, C Buzzoni, L Mangone, R Capocaccia, R De Angelis, R Zanetti, A Maurina, S Pildava, N Lipunova, I Vincerževskienė, D Agius, N Calleja, S Siesling, O Visser, Larønningen, B Møller, A Dyzmann-Sroka, M Trojanowski, S Góźdź, R Mężyk, T Mierzwa, L Molong, J Rachtan, S Szewczyk, J Błaszczyk, K Kępska, B Kościańska, K Tarocińska, M Zwierko, K Drosik, K M Maksimowicz, E Purwin-Porowska, E Reca, J Wójcik-Tomaszewska, A Tukiendorf, M Grądalska-Lampart, A U Radziszewska, A Gos, M Talerczyk, M Wyborska, J A Didkowska, U Wojciechowska, M Bielska-Lasota, G Forjaz de Lacerda, R A Rego, J Bastos, M A Silva, L Antunes, J Laranja Pontes, A Mayer-da-Silva, A Miranda, L M Blaga, D Coza, Russia: M Y Valkov, L Gusenkova, O Lazarevich, O Prudnikova, D M Vjushkov, A G Egorova, A E Orlov, L A Kudyakov, L V Pikalova, J Adamcik, C Safaei Diba, M Primic-Žakelj, V Zadnik, N Larrañaga, A Lopez de Munain, A A Herrera, R Redondas, R Marcos-Gragera, M L Vilardell Gil, E Molina, M J Sánchez Perez, P Franch Sureda, M Ramos Montserrat, M D Chirlaque, C Navarro, E E Ardanaz, M M Guevara, R Fernández-Delgado, R Peris-Bonet, M Carulla, J Galceran, C Alberich, M Vicente-Raneda, S Khan, D Pettersson, P Dickman, I Avelina, K Staehelin, B Camey, C Bouchardy, R Schaar, H Frick, C Herrmann, J L Bulliard, M Maspoli-Conconi, C E Kuehni, S M Redmond, A Bordoni, L Ortelli, A Chiolero, I Konzelmann, K L Matthes, S Rohrmann, Broggio, J Rashbass, D Fitzpatrick, A Gavin, D I Clark, A J Deas, D W Huws, C White, C Allemani, A Bonaventure, M P Coleman, V Di Carlo, R Harewood, M Matz, L Montel, M Nikšić, B Rachet, A D Turculeț, R Stephens, C A Stiller, E Chalker, H Phung, R Walton, H You, S Guthridge, F Johnson, J Aitken, P Gordon, K D'Onise, K Priest, B C Stokes, A Venn, H Farrugia, V Thurs eld, J Dowlin, D Currow, J Hendrix, C Lewis
Subjects: 0301 basic medicine, Universal Health Coverage, population-based registries, Relative Survival, Settore MED/42 - Igiene Generale E Applicata, Cancer -- Treatment, Humans, Neoplasms, Population Surveillance, Registries, Survival Rate, Medicine (all), 0302 clinical medicine, cancer survival, education.field_of_study, Relative survival, EPICENE, General Medicine, 3. Good health, trend, 030220 oncology & carcinogenesis, Public-Health, cancer surveillance, Liver cancer, survival, cancer registry, CONCORD-3, Cure, Childhood-Cancer, medicine.medical_specialty, population-based cancer registries, Womens Cancers, Population, Medicine (all),cancer survival, population-based cancer registries, Socio-culturale, United-States, Article, 03 medical and health sciences, Breast cancer, Cancer epidemiology, medicine, Nordic-Countries, Cancer -- Mortality, education, Survival rate, Cancer prevention, Alternative Approach, business.industry, Public health, Cancer, Cancer -- Patients -- Long-term care, medicine.disease, 030104 developmental biology, High-Income Countries, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Demography
Abstract: Eser, Sultan (Balikesir Author), Background In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of health systems and to inform global policy on cancer control. CONCORD-3 updates the worldwide surveillance of cancer survival to 2014. Methods CONCORD-3 includes individual records for 37.5 million patients diagnosed with cancer during the 15-year period 2000-14. Data were provided by 322 population-based cancer registries in 71 countries and territories, 47 of which provided data with 100% population coverage. The study includes 18 cancers or groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate, and melanoma of the skin in adults, and brain tumours, leukaemias, and lymphomas in both adults and children. Standardised quality control procedures were applied; errors were rectified by the registry concerned. We estimated 5-year net survival. Estimates were age-standardised with the International Cancer Survival Standard weights.Findings For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway, and Sweden. For many cancers, Denmark is closing the survival gap with the other Nordic countries. Survival trends are generally increasing, even for some of the more lethal cancers: in some countries, survival has increased by up to 5% for cancers of the liver, pancreas, and lung. For women diagnosed during 2010-14, 5-year survival for breast cancer is now 89.5% in Australia and 90.2% in the USA, but international differences remain very wide, with levels as low as 66.1% in India. For gastrointestinal cancers, the highest levels of 5-year survival are seen in southeast Asia: in South Korea for cancers of the stomach (68.9%), colon (71.8%), and rectum (71.1%); in Japan for oesophageal cancer (36.0%); and in Taiwan for liver cancer (27.9%). By contrast, in the same world region, survival is generally lower than elsewhere for melanoma of the skin (59.9% in South Korea, 52.1% in Taiwan, and 49.6% in China), and for both lymphoid malignancies (52.5%, 50.5%, and 38.3%) and myeloid malignancies (45.9%, 33.4%, and 24.8%). For children diagnosed during 2010-14, 5-year survival for acute lymphoblastic leukaemia ranged from 49.8% in Ecuador to 95.2% in Finland. 5-year survival from brain tumours in children is higher than for adults but the global range is very wide (from 28.9% in Brazil to nearly 80% in Sweden and Denmark). Interpretation The CONCORD programme enables timely comparisons of the overall effectiveness of health systems in providing care for 18 cancers that collectively represent 75% of all cancers diagnosed worldwide every year. It contributes to the evidence base for global policy on cancer control. Since 2017, the Organisation for Economic Co-operation and Development has used findings from the CONCORD programme as the official benchmark of cancer survival, among their indicators of the quality of health care in 48 countries worldwide. Governments must recognise population-based cancer registries as key policy tools that can be used to evaluate both the impact of cancer prevention strategies and the effectiveness of health systems for all patients diagnosed with cancer., American Cancer Society Centers for Disease Control and Prevention Swiss Re Swiss Cancer Research foundation Swiss Cancer League Institut National du Cancer La Ligue Contre le Cancer Rossy Family Foundation US National Cancer Institute Susan G Komen Foundation
Published: 2018
Full Text: View/download PDF

4. Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000–2007: Results of EUROCARE-5 population-based study

Author: Roberta De Angelis, Pamela Minicozzi, Milena Sant, Luigino Dal Maso, David H. Brewster, Gemma Osca-Gelis, Otto Visser, Marc Maynadié, Rafael Marcos-Gragera, Xavier Troussard, Dominic Agius, Paolo Roazzi, Elisabetta Meneghini, Alain Monnereau, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, P. Mancuso, S. Ferretti, E. Crocetti, A. Caldarella, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, L. Dal Maso, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, S. Busco, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, R. Staiti, F. Vitale, B. Ravazzolo, M. Michiara, R. Tumino, P. Giorgi Rossi, E. Di Felice, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, F. Bianconi, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Guzzinati, S. Pildava, G. Smailyte, N. Calleja, D. Agius, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, M. Bebenek, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, C. Castro, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, C. Ramírez, M. Errezola, J. Bidaurrazaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, R. Marcos-Gragera, A. Izquierdo Font, M.J. Sanchez, D.Y.L. Chang, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, V. Lemmens, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, C. Donnelly, D.H. Brewster, D.W. Huws, C. White, and R. Otter
Subjects: Oncology, Cancer registry, Europe, Hodgkin lymphoma, Leukaemia, Lymphoma, Multiple myeloma, Non-Hodgkin lymphoma, Relative survival, Cancer Research, education.field_of_study, medicine.medical_specialty, Myeloid, business.industry, Population, Follicular lymphoma, Plasma cell neoplasm, medicine.disease, medicine.anatomical_structure, hemic and lymphatic diseases, Internal medicine, Immunology, Medicine, education, business, International Classification of Diseases for Oncology
Abstract: BACKGROUND: Significant advances in the management of patients with lymphoid and myeloid malignancies entered clinical practice in the early 2000's. The EUROCARE-5 study database provides an opportunity to assess the impact of these changes at the population level by country in Europe. We provide survival estimates for clinically relevant haematological malignancies (HM), using the International Classification of Diseases for Oncology 3, by country, gender and age in Europe. METHODS: We estimated age-standardised relative survival using the complete cohort approach for 625, 000 adult patients diagnosed in 2000-2007 and followed up to 2008. Survival information was provided by 89 participating cancer registries from 29 European countries. Mean survival in Europe was calculated as the population weighted average of country-specific estimates. RESULTS: On average in Europe, 5-year relative survival was highest for Hodgkin lymphoma (81% ; 40, 625 cases), poorest for acute myeloid leukaemia (17% ; 57, 026 cases), and intermediate for non- Hodgkin lymphoma (59% ; 329, 204 cases), chronic myeloid leukaemia (53% ; 17, 713 cases) and plasma cell neoplasms (39% ; 94, 024 cases). Survival was generally lower in Eastern Europe and highest in Central and Northern Europe. Wider between country differences (>10%) were observed for malignancies that benefited from therapeutic advances, such as chronic myeloid leukaemia, chronic lymphocytic leukaemia, follicular lymphoma, diffuse large B-cell lymphoma and multiple myeloma. Lower differences (
Published: 2015
Full Text: View/download PDF

5. Survival of adults with primary malignant brain tumours in Europe; Results of the EUROCARE-5 study

Author: Otto Visser, Eva Ardanaz, Laura Botta, Milena Sant, Andrea Tavilla, Pamela Minicozzi, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, P. Mancuso, S. Ferretti, E. Crocetti, A. Caldarella, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, L. Dal Maso, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, S. Busco, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, R. Staiti, F. Vitale, B. Ravazzolo, M. Michiara, R. Tumino, P. Giorgi Rossi, E. Di Felice, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, F. Bianconi, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Guzzinati, S. Pildava, G. Smailyte, N. Calleja, D. Agius, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, M. Bebenek, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, C. Castro, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, C. Ramírez, M. Errezola, J. Bidaurrazaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, R. Marcos-Gragera, A. Izquierdo Font, M.J. Sanchez, D.Y.L. Chang, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, R. Verhoeven, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, C. Donnelly, D.H. Brewster, D.W. Huws, C. White, and R. Otter
Subjects: Oncology, Ependymoma, Cancer Research, medicine.medical_specialty, Pediatrics, Oligoastrocytoma, Relative survival, business.industry, Cancer, Astrocytoma, medicine.disease, Cancer registry, Internal medicine, medicine, Brain tumours, Survival, Oligodendroglioma, business, Pathological
Abstract: Background Primary malignant brain tumours are rare but represent a serious health burden due to their poor survival. This manuscript describes the survival of malignant brain tumours in adults diagnosed 2000–2007 in Europe. Methods For this study we analysed patients archived in 86 European population-based cancer registries, followed up to 31st December 2008. Only primary malignant neuroepithelial brain tumours (with pathological confirmation) and primary malignant unspecified brain tumours without pathological confirmation were included. We estimated 1-year and 5-year relative survival (RS) weighted by age group and country. We also estimated country-specific and age-specific survival, together with survival differences between time periods (for 1999–2001, 2002–2004 and 2005–2007). Results Glioblastoma represents 49% of all brain tumours, followed by other/unspecified astrocytoma (18%), oligodendroglioma/oligoastrocytoma (9%), ependymoma (1.5%) and embryonal tumours (1%). Five-year RS was 20% for all tumours combined, but ranged from 58% for ependymoma to only 6% for glioblastoma and sharply decreased with increasing age. Differences between countries were relatively small, but generally RS in Ireland/United Kingdom (UK) and Eastern Europe was below the average. An increase in 1-year RS (up to 10–12%) was noted over time, being largest in Central and Northern Europe in patients between 45 and 74 years of age. Conclusions Despite an increase in 1-year RS in most European regions, the survival of primary malignant brain tumours is still poor. Disparities between countries were evident, being even larger at the end of the study period than at the beginning, suggesting differences in availability of the latest treatment modalities.
Published: 2015
Full Text: View/download PDF

6. On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007 – Results from the EUROCARE-5 study

Author: Bernd Holleczek, Silvia Rossi, Agius Domenic, Kaire Innos, Pamela Minicozzi, Silvia Francisci, Monika Hackl, Nora Eisemann, Hermann Brenner, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, A. Mazzei, S. Ferretti, E. Crocetti, G. Manneschi, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, A. Zucchetto, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, M. Natali, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, M. Zarcone, F. Vitale, R. Cusimano, M. Michiara, R. Tumino, P. Giorgi Rossi, M. Vicentini, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, A. Rocca, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Tognazzo, S. Pildava, G. Smailyte, N. Calleja, R. Micallef, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, K. Kepska, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, L. Antunes, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, A. Mateos, M. Errezola, N. Larrañaga, A. Torrella-Ramos, J.M. Díaz García, A.I. Marcos-Navarro, R. Marcos-Gragera, L. Vilardell, M.J. Sanchez, E. Molina, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, V. Lemmens, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, D. Fitzpatrick, D.H. Brewster, D.W. Huws, C. White, and R. Otter
Subjects: Cancer Research, medicine.medical_specialty, education.field_of_study, Relative survival, Colorectal cancer, business.industry, Cancer registries, EUROCARE-5 study, Population-based, Population, Age at diagnosis, Cancer, Rectum, Treatment options, medicine.disease, digestive system diseases, Surgery, medicine.anatomical_structure, Oncology, Internal medicine, Cohort, medicine, business, education
Abstract: Background Previous population-based studies revealed major variation in survival for patients with colorectal cancer (CRC) in Europe by age and between different countries and regions, but also a sustained improvement in survival for patients with CRC in recent years. This EUROCARE-5 paper aims to update available knowledge from previous studies and to provide the latest survival estimates for CRC patients from Europe. Methods The study analysed data of patients diagnosed with CRC from population-based cancer registries diagnosed in 29 European countries. Estimates of 1-year and 5-year relative survival (RS) were derived for patients diagnosed in 2000–2007 by European region, country and age at diagnosis. Additionally to these cohort estimates, time trends in 5-year RS were obtained for the calendar periods 1999–2001 and 2005–2007, using the period analysis methodology. Results European average 5-year RS for patients diagnosed with colon and rectum cancer was 57% and 56%, respectively. The analyses showed persistent differences in cancer survival across Europe with lowest survival for CRC patients observed in Eastern Europe. The analyses further showed a strong gradient in age-specific survival. Even though the study revealed sustained improvement in patient survival between 1999–2001 and 2005–2007 (absolute increase of 4 and 6 percentage points for colon and rectum, respectively), the differences in the survival for CRC patients observed at the beginning of the millennium persisted over time. Conclusion Although survival for CRC patients in Europe improved markedly in the study period, significant geographic variations and a strong age gradient still persisted. Enhanced access to effective diagnostic procedures and treatment options might be the keys to reducing the existing disparities in the survival of CRC patients across Europe.
Published: 2015
Full Text: View/download PDF

7. Survival of women with cancers of breast and genital organs in Europe 1999–2007: Results of the EUROCARE-5 study

Author: Milena Sant, Maria Dolores Chirlaque Lopez, Roberto Agresti, Maria José Sánchez Pérez, Bernd Holleczek, Magdalena Bielska-Lasota, Nadya Dimitrova, Kaire Innos, Alexander Katalinic, Hilde Langseth, Nerea Larrañaga, Silvia Rossi, Sabine Siesling, Pamela Minicozzi, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, P. Mancuso, S. Ferretti, E. Crocetti, A. Caldarella, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, L. Dal Maso, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, S. Busco, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, R. Staiti, F. Vitale, B. Ravazzolo, M. Michiara, R. Tumino, P. Giorgi Rossi, E. Di Felice, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, F. Bianconi, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Guzzinati, S. Pildava, G. Smailyte, N. Calleja, D. Agius, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, M. Bebenek, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, C. Castro, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, C. Ramírez, M. Errezola, J. Bidaurrazaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, R. Marcos-Gragera, A. Izquierdo Font, M.J. Sanchez, D.Y.L. Chang, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, V. Lemmens, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, C. Donnelly, D.H. Brewster, D.W. Huws, C. White, R. Otter, Health Technology & Services Research, and Faculty of Behavioural, Management and Social Sciences
Subjects: Gynecology, Cervical cancer, Cancer Research, medicine.medical_specialty, education.field_of_study, Vaginal cancer, Relative survival, business.industry, Obstetrics, Population, Cancer, Breast cancer, Corpus uteri cancer, Europe, Ovarian cancer, Population-based, Survival, Vulval cancer, Vulvar cancer, medicine.disease, medicine.anatomical_structure, Oncology, medicine, METIS-311843, IR-97294, business, education, Cervix
Abstract: BACKGROUND: Survival differences across Europe for patients with cancers of breast, uterus, cervix, ovary, vagina and vulva have been documented by previous EUROCARE studies. In the present EUROCARE-5 study we update survival estimates and investigate changes in country-specific and over time survival, discussing their relationship with incidence and mortality dynamics for cancers for which organised screening programs are ongoing. METHODS: We analysed cases archived in over 80 population-based cancer registries in 29 countries grouped into five European regions. We used the cohort approach to estimate 5-year relative survival (RS) for adult (⩾15years) women diagnosed 2000-2007, by age, country and region ; and the period approach to estimate time trends (1999-2007) in RS for breast and cervical cancers. RESULTS: In 2000-2007, 5-year RS was 57% overall, 82% for women diagnosed with breast, 76% with corpus uteri, 62% with cervical, 38% with ovarian, 40% with vaginal and 62% with vulvar cancer. Survival was low for patients resident in Eastern Europe (34% ovary-74% breast) and Ireland and the United Kingdom [Ireland/UK] (31-79%) and high for those resident in Northern Europe (41-85%) except Denmark. Survival decreased with advancing age: markedly for women with ovarian (71% 15-44years ; 20% ⩾75years) and breast (86% ; 72%) cancers. Survival for patients with breast and cervical cancers increased from 1999-2001 to 2005-2007, remarkably for those resident in countries with initially low survival. CONCLUSIONS: Despite increases over time, survival for women's cancers remained poor in Eastern Europe, likely due to advanced stage at diagnosis and/or suboptimum access to adequate care. Low survival for women living in Ireland/UK and Denmark could indicate late detection, possibly related also to referral delay. Poor survival for ovarian cancer across the continent and over time suggests the need for a major research effort to improve prognosis for this common cancer.
Published: 2015
Full Text: View/download PDF

8. Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study

Author: Emanuele Crocetti, Sandra Mallone, Trude Eid Robsahm, Anna Gavin, Domenic Agius, Eva Ardanaz, Maria-Dolores Chirlaque Lopez, Kaire Innos, Pamela Minicozzi, Lorenzo Borgognoni, Daniela Pierannunzio, Nora Eisemann, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert- Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, P. Mancuso, S. Ferretti, A. Caldarella, G. Manneschi, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, L. Dal Maso, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, null Santaquilani, A. Tavilla, F. Pannozzo, M. Natali, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, R. Staiti, F. Vitale, B. Ravazzolo, M. Michiara, R. Tumino, P. Giorgi Rossi, E. Di Felice, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, F. Bianconi, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Guzzinati, S. Pildava, G. Smailyte, null Calleja, D. Agius, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, M. Bebenek, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, C. Castro, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, C. Ramírez, M. Errezola, J. Bidaurrazaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, R. Marcos-Gragera, A. Izquierdo Font, M.J. Sanchez, D.Y.L. Chang, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, V. Lemmens, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, C. Donnelly, D.H. Brewster, D.W. Huws, C. White, and R. Otter
Subjects: Pathology, medicine.medical_specialty, European populations, Cancer Research, Relative survival, business.industry, Time trends, Cancer survival, EUROCARE, Registries, Skin melanoma, Confidence interval, Eastern european, Oncology, SDG 3 - Good Health and Well-being, medicine, Overdiagnosis, business, Demography
Abstract: Background In Europe skin melanoma (SM) survival has increased over time. The aims were to evaluate recent trends and differences between countries and regions of Europe.Methods Relative survival (RS) estimates and geographical comparisons were based on 241,485 patients aged 15 years and over with a diagnosis of invasive SM in Europe (2000-2007). Survival time trends during 1999-2007 were estimated using the period approach, for 213,101 patients. Age, gender, sub-sites and morphology subgroups were considered. Results In European patients, estimated 5-year RS was 83% (95% confidence interval, CI 83-84%). The highest values were found for patients resident in Northern (88%; 87-88%) and Central (88%; 87-88%) Europe, followed by Ireland and United Kingdom (UK) (86%; 85-86%) and Southern Europe (83%; 82-83%). The lowest survival was in Eastern Europe (74%; 74-75%). Within regions the intercountry absolute difference in percentage points of RS varied from 4% (North) to 34% (East). RS decreased markedly with patients' age and was higher in women than men. Differences according to SM morphology and skin sub-sites also emerged. Survival has slightly increased from 1999 to 2007, with a small improvement in Northern and the most pronounced improvement in Eastern Europe. Discussion SM survival is high and still increasing in European patients. The gap between Northern and Southern and especially Eastern European countries, although still present, diminished over time. Differences in stage distribution at diagnosis may explain most of the geographical differences. However, part of the improvement in survival may be attributed to overdiagnosis from early diagnosis practices.
Published: 2015
Full Text: View/download PDF

9. Survival patterns in lung and pleural cancer in Europe 1999-2007: Results from the EUROCARE-5 study

Author: Silvia Francisci, Pamela Minicozzi, Daniela Pierannunzio, Eva Ardanaz, Andrea Eberle, Tom K. Grimsrud, Arnold Knijn, Ugo Pastorino, Diego Salmerón, Annalisa Trama, Milena Sant, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, P. Mancuso, S. Ferretti, E. Crocetti, A. Caldarella, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, L. Dal Maso, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, S. Busco, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, R. Staiti, F. Vitale, B. Ravazzolo, M. Michiara, R. Tumino, P. Giorgi Rossi, E. Di Felice, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, F. Bianconi, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Guzzinati, S. Pildava, G. Smailyte, N. Calleja, D. Agius, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, M. Bebenek, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, C. Castro, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, C. Ramírez, M. Errezola, J. Bidaurrazaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, R. Marcos-Gragera, A. Izquierdo Font, M.J. Sanchez, D.Y.L. Chang, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, M. Aarts, R. Damhuis, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, C. Donnelly, D.H. Brewster, D.W. Huws, C. White, and R. Otter
Subjects: Oncology, Cancer Research, medicine.medical_specialty, Lung, Relative survival, business.industry, Large cell, Cancer, respiratory system, medicine.disease, Europe, Lung cancer, Morphology, Pleural cancer, Population-based cancer registries, Survival trends, Surgery, respiratory tract diseases, medicine.anatomical_structure, Internal medicine, Epidemiology of cancer, medicine, Carcinoma, Mesothelioma, business
Abstract: Background Survival of patients diagnosed with lung and pleura cancer is a relevant health care indicator which is related to the availability and access to early diagnosis and treatment facilities. Aim of this paper is to update lung and pleural cancer survival patterns and time trends in Europe using the EUROCARE-5 database. Methods Data on adults diagnosed with lung and pleural cancer from 87 European cancer registries in 28 countries were analysed. Relative survival (RS) in 2000–2007 by country/region, age and gender, and over time trends in 1999–2007 were estimated. Results Lung cancer survival is poor everywhere in Europe, with a RS of 39% and 13% at 1 and 5 years since diagnosis, respectively. A geographical variability is present across European areas with a maximum regional difference of 12 and 5 percentage points in 1-year and 5-year RS respectively. Pleural cancer represents 4% of cases included in the present study with 7% 5-year RS overall in Europe. Most pleural cancers (83%) are microscopically verified mesotheliomas. Survival for both cancers decreases with advancing age at diagnosis for both cancers. Slight increasing trends are described for lung cancer. Survival over time is higher for squamous cell carcinoma and adenocarcinomas than for small and large cell carcinoma; and better among women than men. Conclusions Despite the generalised although slight increase, survival of lung and pleural cancer patients still remains poor in European countries. Priority should be given to prevention, with tobacco control policies across Europe for lung cancer and banning asbestos exposure for pleural cancer, and in early diagnosis and better treatment. The management of mesothelioma needs a multidisciplinary team and standardised health care strategies.
Published: 2015

10. Age and case mix-standardised survival for all cancer patients in Europe 1999-2007: Results of EUROCARE-5, a population-based study

Author: Paolo Baili, Francesca Di Salvo, Rafael Marcos-Gragera, Sabine Siesling, Sandra Mallone, Mariano Santaquilani, Andrea Micheli, Roberto Lillini, Silvia Francisci, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, A. Mazzei, S. Ferretti, E. Crocetti, G. Manneschi, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, A. Zucchetto, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, M. Natali, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, M. Zarcone, F. Vitale, R. Cusimano, M. Michiara, R. Tumino, P. Giorgi Rossi, M. Vicentini, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, A. Rocca, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Tognazzo, S. Pildava, G. Smailyte, N. Calleja, R. Micallef, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, K. Kepska, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, L. Antunes, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, A. Mateos, M. Errezola, N. Larrañaga, A. Torrella-Ramos, J.M. Díaz García, A.I. Marcos-Navarro, R. Marcos-Gragera, L. Vilardell, M.J. Sanchez, E. Molina, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, V. Lemmens, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, D. Fitzpatrick, D.H. Brewster, D.W. Huws, C. White, R. Otter, Baili P., Salvo F.D., Marcos-Gragera R., Siesling S., Mallone S., Santaquilani M., Micheli A., Lillini R., Francisci S., Hackl M., Zielonke N., Oberaigner W., Eycken E.V., Henau K., Valerianova Z., Dimitrova N., Sekerija M., Zvolsky M., Dusek L., Storm H., Engholm G., Magi M., Aareleid T., Malila N., Seppa K., Velten M., Troussard X., Bouvier V., Launoy G., Guizard A.V., Faivre J., Bouvier A.M., Arveux P., Maynadie M., Woronoff A.S., Robaszkiewicz M., Baldi I., Monnereau A., Tretarre B., Bossard N., Belot A., Colonna M., Molinie F., Bara S., Schvartz C., Lapotre-Ledoux B., Grosclaude P., Meyer M., Stabenow R., Luttmann S., Eberle A., Brenner H., Nennecke A., Engel J., Schubert-Fritschle G., Kieschke J., Heidrich J., Holleczek B., Katalinic A., Jonasson J.G., Tryggvadottir L., Comber H., Mazzoleni G., Bulatko A., Buzzoni C., Giacomin A., Sardo A.S., Mazzei A., Ferretti S., Crocetti E., Manneschi G., Gatta G., Sant M., Amash H., Amati C., Berrino F., Bonfarnuzzo S., Botta L., Foschi R., Margutti C., Meneghini E., Minicozzi P., Trama A., Serraino D., Zucchetto A., Angelis R.D., Caldora M., Capocaccia R., Carrani E., Pierannunzio D., Roazzi P., Rossi S., Tavilla A., Pannozzo F., Natali M., Bonelli L., Vercelli M., Gennaro V., Ricci P., Autelitano M., Randi G., Ponz De Leon M., Marchesi C., Cirilli C., Fusco M., Vitale M.F., Usala M., Traina A., Zarcone M., Vitale F., Cusimano R., Michiara M., Tumino R., Rossi P.G., Vicentini M., Falcini F., Iannelli A., Sechi O., Cesaraccio R., Piffer S., Madeddu A., Tisano F., Maspero S., Fanetti A.C., Zanetti R., Rosso S., Candela P., Scuderi T., Stracci F., Rocca A., Tagliabue G., Contiero P., Tos A.P.D., Tognazzo S., Pildava S., Smailyte G., Calleja N., Micallef R., Johannesen T.B., Rachtan J., Gozdz S., Me zyk R., Baszczyk J., Kepska K., Bielska-Lasota M., Forjaz de Lacerda G., Bento M.J., Antunes L., Miranda A., Mayer-Da-silva A., Nicula F., Coza D., Diba C.S., Primic-Zakelj M., Almar E., Mateos A., Errezola M., Larranaga N., Torrella-Ramos A., Garcia J.M.D., Marcos-Navarro A.I., Vilardell L., Sanchez M.J., Navarro C., Moreno-Iribas C., Ardanaz E., Galceran J., Lambe M., Khan S., Mousavi M., Bouchardy C., Ess S.M., Frick H., Lorez M., Herrmann C., Bordoni A., Spitale A., Konzelmann I., Visser O., Lemmens V., Coleman M., Allemani C., Rachet B., Verne J., Easey N., Lawrence G., Moran T., Rashbass J., Roche M., Wilkinson J., Gavin A., Fitzpatrick D., Brewster D.H., Huws D.W., White C., Baili, P, Di Salvo, F, Marcos Gragera, R, Siesling, S, Mallone, S, Santaquilani, M, Micheli, A, Lillini, R, Francisci, S, Health Technology & Services Research, and Faculty of Behavioural, Management and Social Sciences
Subjects: Cancer Research, Population, Population-based cancer registrie, All cancer, Gross domestic product, Case-mix by cancer site, Case mix index, Health care, Medicine, education, METIS-311842, education.field_of_study, Relative survival, business.industry, Cancer, Cancer survival, Population-based cancer registries, medicine.disease, Eastern european, Oncology, EUROCARE, business, IR-97293, Demography
Abstract: Background: Overall survival after cancer is frequently used when assessing a health care service’s performance as a whole. It is mainly used by the public, politicians and the media, and is often dismissed by clinicians because of the heterogeneous mix of different cancers, risk factors and treatment modalities. Here we give survival details for all cancers combined in Europe, correlating it with economic variables to suggest reasons for differences. Methods: We computed age and cancer site case- mix standardised relative survival for all cancers combined (ACRS) for 29 countries participating in the EUROCARE-5 project with data on more than 7.5 million cancer cases from 87 population-based cancer registries, using complete and period approach. Results: Denmark, United Kingdom (UK) and Eastern European countries had lower survival than neighbouring countries. Five-year ACRS has been increasing throughout Europe, and substantial increases, between 1999–2001 and 2005–2007, have been achieved in countries where survival was lower in the past. Five-year ACRS for men and women are positively correlated with macro-economic variables like the Gross Domestic Product (GDP) and Total National Expenditure on Health (TNEH) (R2 about 70%). Countries with recent larger increases in GDP and TNEH had greater increases in cancer survival. Conclusions: ACRS serves to compare all cancer survival in Europe taking account of the geographical variability in case-mixes. The EUROCARE-5 data on ACRS confirm previous EUROCARE findings. Survival appears to correlate with macro-economic determinants, particularly with investments in the health care system.
Published: 2015

11. Urinary tract cancer survival in Europe 1999-2007: Results of the population-based study EUROCARE-5

Author: Rafael Marcos-Gragera, Sandra Mallone, Lambertus A. Kiemeney, Loreto Vilardell, Núria Malats, Yves Allory, Milena Sant, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A. M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, A. Mazzei, S. Ferretti, E. Crocetti, G. Manneschi, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, A. Zucchetto, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, S. Busco, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, M. Zarcone, F. Vitale, R. Cusimano, M. Michiara, R. Tumino, P. Giorgi Rossi, M. Vicentini, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, A. Rocca, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Tognazzo, S. Pildava, G. Smailyte, N. Calleja, R. Micallef, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, K. Kepska, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, L. Antunes, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, A. Mateos, M. Errezola, N. Larrañaga, A. Torrella-Ramos, J.M. Díaz García, A.I. Marcos-Navarro, R. Marcos-Gragera, L. Vilardell, M.J. Sanchez, E. Molina, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, K. Aben, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, D. Fitzpatrick, D.H. Brewster, D.W. Huws, C. White, R. Otter, Marcos-Gragera R., Mallone S., Kiemeney L.A., Vilardell L., Malats N., Allory Y., Sant M., Hackl M., Zielonke N., Oberaigner W., Eycken E.V., Henau K., Valerianova Z., Dimitrova N., Sekerija M., Zvolsky M., Dusek L., Storm H., Engholm G., Magi M., Aareleid T., Malila N., Seppa K., Velten M., Troussard X., Bouvier V., Launoy G., Guizard A.V., Faivre J., Bouvier A.M., Arveux P., Maynadie M., Woronoff A.S., Robaszkiewicz M., Baldi I., Monnereau A., Tretarre B., Bossard N., Belot A., Colonna M., Molinie F., Bara S., Schvartz C., Lapotre-Ledoux B., Grosclaude P., Meyer M., Stabenow R., Luttmann S., Eberle A., Brenner H., Nennecke A., Engel J., Schubert-Fritschle G., Kieschke J., Heidrich J., Holleczek B., Katalinic A., Jonasson J.G., Tryggvadottir L., Comber H., Mazzoleni G., Bulatko A., Buzzoni C., Giacomin A., Sardo A.S., Mazzei A., Ferretti S., Crocetti E., Manneschi G., Gatta G., Amash H., Amati C., Baili P., Berrino F., Bonfarnuzzo S., Botta L., Salvo F.D., Foschi R., Margutti C., Meneghini E., Minicozzi P., Trama A., Serraino D., Zucchetto A., Angelis R.D., Caldora M., Capocaccia R., Carrani E., Francisci S., Pierannunzio D., Roazzi P., Rossi S., Santaquilani M., Tavilla A., Pannozzo F., Busco S., Bonelli L., Vercelli M., Gennaro V., Ricci P., Autelitano M., Randi G., Ponz De Leon M., Marchesi C., Cirilli C., Fusco M., Vitale M.F., Usala M., Traina A., Zarcone M., Vitale F., Cusimano R., Michiara M., Tumino R., Rossi P.G., Vicentini M., Falcini F., Iannelli A., Sechi O., Cesaraccio R., Piffer S., Madeddu A., Tisano F., Maspero S., Fanetti A.C., Zanetti R., Rosso S., Candela P., Scuderi T., Stracci F., Rocca A., Tagliabue G., Contiero P., Tos A.P.D., Tognazzo S., Pildava S., Smailyte G., Calleja N., Micallef R., Johannesen T.B., Rachtan J., Gozdz S., Me zyk R., Baszczyk J., Kepska K., Bielska-Lasota M., Forjaz de Lacerda G., Bento M.J., Antunes L., Miranda A., Mayer-Da-silva A., Nicula F., Coza D., Diba C.S., Primic-Zakelj M., Almar E., Mateos A., Errezola M., Larranaga N., Torrella-Ramos A., Garcia J.M.D., Marcos-Navarro A.I., Sanchez M.J., Molina E., Navarro C., Chirlaque M.D., Moreno-Iribas C., Ardanaz E., Galceran J., Carulla M., Lambe M., Khan S., Mousavi M., Bouchardy C., Usel M., Ess S.M., Frick H., Lorez M., Herrmann C., Bordoni A., Spitale A., Konzelmann I., Visser O., Aben K., Coleman M., Allemani C., Rachet B., Verne J., Easey N., Lawrence G., Moran T., Rashbass J., Roche M., Wilkinson J., Gavin A., Fitzpatrick D., Brewster D.H., Huws D.W., and White C.
Subjects: Cancer Research, medicine.medical_specialty, Urinary system, Population, Population-based cancer registrie, Internal medicine, Medicine, education, Gynecology, education.field_of_study, Urinary bladder, Relative survival, business.industry, Urinary bladder tumours, Cancer survival, EUROCARE, Kidney cancer, Population-based cancer registries, Cancer, medicine.disease, Population based study, medicine.anatomical_structure, Oncology, business
Abstract: Background This work presents relative survival estimates regarding urinary tract tumours among adult patients (age ⩾ 15 years) diagnosed in Europe. It reports on survival estimates of cases diagnosed in 2000–2007, and on survival time trends from 1999–2001 to 2005–2007. Methods Data on 677,340 adult urinary tract tumour patients, (429,154 cases of invasive and non-invasive bladder and 248,186 cases of invasive kidney cancers) diagnosed between 2000 and 2007 were provided by 86 population-based cancer registries from 29 European countries. The complete approach was used to estimate survival in 2000–2007; the period approach was used to estimate survival over time. Results The age-standardised 5-year relative survival for patients with kidney tumours diagnosed in Europe during 2000–2007 was 60%. The best prognosis was observed in Southern and Central Europe and prognosis improved in all regions along the time period. For invasive and non-invasive patients with bladder tumours combined the age-standardised 5-year relative survival in Europe was 68%. The best prognosis was observed in Southern and Northern Europe. However, in Scotland and The Netherlands the relative survival was significantly lower, although the survival estimates for these two countries were based on invasive tumours only. Conclusions Differences in registration practices affect comparisons of survival values between European countries, especially in patients with urinary bladder cancers. The between-country variation in survival is influenced by the varying use of diagnostic investigation in urinary tract tumours. Further data on stage at diagnosis can help to elucidate the influence of diagnostic intensity or early diagnosis on the survival patterns.
Published: 2015

12. Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study

Author: Gemma Gatta, Laura Botta, María José Sánchez, Lesley Ann Anderson, Daniela Pierannunzio, Lisa Licitra, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, A. Mazzei, S. Ferretti, E. Crocetti, G. Manneschi, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, A. Zucchetto, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, M. Natali, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, M. Zarcone, F. Vitale, R. Cusimano, M. Michiara, R. Tumino, P. Giorgi Rossi, M. Vicentini, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, A. Rocca, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Tognazzo, S. Pildava, G. Smailyte, N. Calleja, R. Micallef, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, K. Kepska, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, L. Antunes, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, A. Mateos, M. Errezola, N. Larrañaga, A. Torrella-Ramos, J.M. Díaz García, A.I. Marcos-Navarro, R. Marcos-Gragera, L. Vilardell, M.J. Sanchez, E. Molina, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, B. van Dijk, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, D. Fitzpatrick, D.H. Brewster, D.W. Huws, C. White, and R. Otter
Subjects: Larynx, Cancer Research, medicine.medical_specialty, Relative survival, business.industry, Advanced stage, Cancer, Disease, medicine.disease, Surgery, Population based study, medicine.anatomical_structure, Oncology, Europe, Head and neck cancers, Hypopharynx, Nasopharynx, Oral cavity, Oropharynx, Population-based study, Survival, Tongue, Internal medicine, Medicine, Stage (cooking), business, Head and neck
Abstract: BACKGROUND: Head and neck (H&N) cancers are a heterogeneous group of malignancies, affecting various sites, with different prognoses. The aims of this study are to analyse survival for patients with H&N cancers in relation to tumour location, to assess the change in survival between European countries, and to investigate whether survival improved over time. METHODS: We analysed about 250, 000 H&N cancer cases from 86 cancer registries (CRs). Relative survival (RS) was estimated by sex, age, country and stage. We described survival time trends over 1999-2007, using the period approach. Model based survival estimates of relative excess risks (RERs) of death were also provided by country, after adjusting for sex, age and sub- site. RESULTS: Five-year RS was the poorest for hypopharynx (25%) and the highest for larynx (59%). Outcome was significantly better in female than in male patients. In Europe, age-standardised 5-year survival remained stable from 1999-2001 to 2005-2007 for laryngeal cancer, while it increased for all the other H&N cancers. Five- year age-standardised RS was low in Eastern countries, 47% for larynx and 28% for all the other H&N cancers combined, and high in Ireland and the United Kingdom (UK), and Northern Europe (62% and 46%). Adjustment for sub-site narrowed the difference between countries. Fifty-four percent of patients was diagnosed at advanced stage (regional or metastatic). Five- year RS for localised cases ranged between 42% (hypopharynx) and 74% (larynx). CONCLUSIONS: This study shows survival progresses during the study period. However, slightly more than half of patients were diagnosed with regional or metastatic disease at diagnosis. Early diagnosis and timely start of treatment are crucial to reduce the European gap to further improve H&N cancers outcome.
Published: 2015

13. Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999- 2007: Results of EUROCARE-5

Author: Côme Lepage, Riccardo Capocaccia, Monika Hackl, Valerie Lemmens, Esther Molina, Daniela Pierannunzio, Milena Sant, Annalisa Trama, Jean Faivre, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, P. Mancuso, S. Ferretti, E. Crocetti, A. Caldarella, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, L. Dal Maso, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, S. Busco, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, R. Staiti, F. Vitale, B. Ravazzolo, M. Michiara, R. Tumino, P. Giorgi Rossi, E. Di Felice, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, F. Bianconi, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Guzzinati, S. Pildava, G. Smailyte, N. Calleja, D. Agius, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, M. Bebenek, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, C. Castro, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, C. Ramírez, M. Errezola, J. Bidaurrazaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, R. Marcos-Gragera, A. Izquierdo Font, M.J. Sanchez, D.Y.L. Chang, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, L. van der Geest, R. Otter, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, C. Donnelly, D.H. Brewster, D.W. Huws, C. White, Lepage C., Capocaccia R., Hackl M., Lemmens V., Molina E., Pierannunzio D., Sant M., Trama A., Faivre J., Zielonke N., Oberaigner W., Van Eycken E., Henau K., Valerianova Z., Dimitrova N., Sekerija M., Zvolsky M., Dus?ek L., Storm H., Engholm G., Ma gi M., Aareleid T., Malila N., Seppa K., Velten M., Troussard X., Bouvier V., Launoy G., Guizard A.V., Bouvier A.M., Arveux P., Maynadie M., Woronoff A.S., Robaszkiewicz M., Baldi I., Monnereau A., Tretarre B., Bossard N., Belot A., Colonna M., Molinie F., Bara S., Schvartz C., Lapo tre-Ledoux B., Grosclaude P., Meyer M., Stabenow R., Luttmann S., Eberle A., Brenner H., Nennecke A., Engel J., Schubert-Fritschle G., Kieschke J., Heidrich J., Holleczek B., Katalinic A., Jo nasson J.G., Tryggvadottir L., Comber H., Mazzoleni G., Bulatko A., Buzzoni C., Giacomin A., Sutera Sardo A., Mancuso P., Ferretti S., Crocetti E., Caldarella A., Gatta G., Amash H., Amati C., Baili P., Berrino F., Bonfarnuzzo S., Botta L., Di Salvo F., Foschi R., Margutti C., Meneghini E., Minicozzi P., Serraino D., Dal Maso L., De Angelis R., Caldora M., Carrani E., Francisci S., Mallone S., Roazzi P., Rossi S., Santaquilani M., Tavilla A., Pannozzo F., Busco S., Bonelli L., Vercelli M., Gennaro V., Ricci P., Autelitano M., Randi G., Ponz De Leon M., Marchesi C., Cirilli C., Fusco M., Vitale M.F., Usala M., Traina A., Staiti R., Vitale F., Ravazzolo B., Michiara M., Tumino R., Giorgi Rossi P., Di Felice E., Falcini F., Iannelli A., Sechi O., Cesaraccio R., Piffer S., Madeddu A., Tisano F., Maspero S., C. Fanetti A., Zanetti R., Rosso S., Candela P., Scuderi T., Stracci F., Bianconi F., Tagliabue G., Contiero P., Dei Tos A.P., Guzzinati S., Pildava S., Smailyte G., Calleja N., Agius D., Johannesen T.B., Rachtan J., Go zdz S., Me zyk R., Baszczyk J., Bebenek M., Bielska-Lasota M., Forjaz de Lacerda G., Bento M.J., Castro C., Miranda A., Mayer-da-Silva A., Nicula F., Coza D., Safaei Diba C., Primic-Zakelj M., Almar E., Ramirez C., Errezola M., Bidaurrazaga J., Torrella-Ramos A., Diaz Garcia J.M., Jimenez-Chillaron R., Marcos-Gragera R., Izquierdo Font A., Sanchez M.J., Chang D.Y.L., Navarro C., Chirlaque M.D., Moreno-Iribas C., Ardanaz E., Galceran J., Carulla M., Lambe M., Khan S., Mousavi M., Bouchardy C., Usel M., Ess S.M., Frick H., Lorez M., Herrmann C., Bordoni A., Spitale A., Konzelmann I., Visser O., van der Geest L., Otter R., Coleman M., Allemani C., Rachet B., Verne J., Easey N., Lawrence G., Moran T., Rashbass J., Roche M., Wilkinson J., Gavin A., Donnelly C., Brewster D.H., Huws D.W., and White C.
Subjects: Cancer Research, medicine.medical_specialty, Survival, Biliary tract cancer, Cancer registry, Europe, Pancreatic cancer, Primary liver cancer, Time trends in survival, Oncology, Population, Socio-culturale, Gastroenterology, Internal medicine, medicine, education, Survival analysis, education.field_of_study, Relative survival, business.industry, Gallbladder, Cancer, medicine.disease, medicine.anatomical_structure, Liver cancer, business
Abstract: Background The EUROCARE study collects and analyses survival data from population-based cancer registries (CRs) in Europe in order to provide data on between-country differences in survival and time trends in survival. Methods This study analyses data on liver cancer, gallbladder and extrahepatic biliary tract cancers (“biliary tract cancers”), and pancreatic cancer diagnosed in 2000–2007 from 88 CRs in 29 countries. Relative survival (RS) was estimated overall, by region, sex, age and period of diagnosis using the complete approach. Time trends in 5-year RS over 1999–2007 were also analysed using the period approach. Results The prognosis of the studied cancers was poor. Age-standardised 5-year RS was 12% for liver cancer, 17% for biliary tract cancers and 7% for pancreatic cancer. There were some between-country differences in survival. In general, RS was low in Eastern Europe and high in Central and Southern Europe. For all sites, 5-year RS was similar in men and women and decreased with advancing age. No substantial changes in survival were reported for pancreatic cancer over the period 1999–2007. On average, there was a crude increase in 5-year RS of 3 percentage points between the periods 1999–2001 and 2005–2007 for liver cancer and biliary tract cancers. Conclusions The major changes in imaging techniques over the study period for the diagnosis of the three studied cancers did not result in an improvement in the prognosis of these cancers. In the near future, new innovative treatments might be the best way to improve the prognosis in these cancers.
Published: 2015

14. Survival of male genital cancers (prostate, testis and penis) in Europe 1999-2007: Results from the EUROCARE-5 study

Author: Annalisa Trama, Roberto Foschi, Nerea Larrañaga, Milena Sant, Rafael Fuentes-Raspall, Diego Serraino, Andrea Tavilla, Liesbet Van Eycken, Nicola Nicolai, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, P. Mancuso, S. Ferretti, E. Crocetti, A. Caldarella, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, L. Dal Maso, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, S. Busco, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M. F. Vitale, M. Usala, A. Traina, R. Staiti, F. Vitale, B. Ravazzolo, M. Michiara, R. Tumino, P. Giorgi Rossi, E. Di Felice, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, F. Bianconi, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Guzzinati, S. Pildava, G. Smailyte, N. Calleja, D. Agius, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, M. Bebenek, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, C. Castro, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, C. Ramírez, M. Errezola, J. Bidaurrazaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, R. Marcos-Gragera, A. Izquierdo Font, M. J. Sanchez, D.Y.L. Chang, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S. M. Ess, H. Frick, M. Lorez, S.M. Ess, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, R. Verhoeven, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, C. Donnelly, D.H. Brewster, D.W. Huws, C. White, R. Otter, Trama A., Foschi R., Larranaga N., Sant M., Fuentes-Raspall R., Serraino D., Tavilla A., Eycken L.V., Nicolai N., Hackl M., Zielonke N., Oberaigner W., Eycken E.V., Henau K., Valerianova Z., Dimitrova N., Sekerija M., Zvolsky M., Dusek L., Storm H., Engholm G., Magi M., Aareleid T., Malila N., Seppa K., Velten M., Troussard X., Bouvier V., Launoy G., Guizard A.V., Faivre J., Bouvier A.M., Arveux P., Maynadie M., Woronoff A.S., Robaszkiewicz M., Baldi I., Monnereau A., Tretarre B., Bossard N., Belot A., Colonna M., Molinie F., Bara S., Schvartz C., Lapotre-Ledoux B., Grosclaude P., Meyer M., Stabenow R., Luttmann S., Eberle A., Brenner H., Nennecke A., Engel J., Schubert-Fritschle G., Kieschke J., Heidrich J., Holleczek B., Katalinic A., Jonasson J.G., Tryggvadottir L., Comber H., Mazzoleni G., Bulatko A., Buzzoni C., Giacomin A., Sardo A.S., Mazzei A., Ferretti S., Crocetti E., Manneschi G., Gatta G., Amash H., Amati C., Baili P., Berrino F., Bonfarnuzzo S., Botta L., Salvo F.D., Margutti C., Meneghini E., Minicozzi P., Zucchetto A., Angelis R.D., Caldora M., Capocaccia R., Carrani E., Francisci S., Mallone S., Pierannunzio D., Roazzi P., Rossi S., Santaquilani M., Pannozzo F., Busco S., Bonelli L., Vercelli M., Gennaro V., Ricci P., Autelitano M., Randi G., Ponz De Leon M., Marchesi C., Cirilli C., Fusco M., Vitale M.F., Usala M., Traina A., Zarcone M., Vitale F., Cusimano R., Michiara M., Tumino R., Rossi P.G., Vicentini M., Falcini F., Iannelli A., Sechi O., Cesaraccio R., Piffer S., Madeddu A., Tisano F., Maspero S., Fanetti A.C., Zanetti R., Rosso S., Candela P., Scuderi T., Stracci F., Rocca A., Tagliabue G., Contiero P., Tos A.P.D., Tognazzo S., Pildava S., Smailyte G., Calleja N., Micallef R., Johannesen T.B., Rachtan J., Gozdz S., Gozdz R., Me zyk J., Kepska K., Bielska-Lasota M., Forjaz de Lacerda G., Bento M.J., Antunes L., Miranda A., Mayer-Da-silva A., Nicula F., Coza D., Diba C.S., Primic-Zakelj M., Almar E., Mateos A., Errezola M., Torrella-Ramos A., Garcia J.M.D., Marcos-Navarro A.I., Marcos-Gragera R., Vilardell L., Sanchez M.J., Molina E., Navarro C., Chirlaque M.D., Moreno-Iribas C., Ardanaz E., Galceran J., Carulla M., Lambe M., Khan S., Mousavi M., Bouchardy C., Usel M., Ess S.M., Frick H., Lorez M., Herrmann C., Bordoni A., Spitale A., Konzelmann I., Visser O., Aben K., Coleman M., Allemani C., Rachet B., Verne J., Easey N., Lawrence G., Moran T., Rashbass J., Roche M., Wilkinson J., Gavin A., Fitzpatrick D., Brewster D.H., Huws D.W., and White C.
Subjects: Oncology, Cancer Research, medicine.medical_specialty, Survival, Relative survival, business.industry, Cancer registrie, Incidence (epidemiology), Prostate, Cancer, Penile cancer, medicine.disease, Prostate cancer, medicine.anatomical_structure, Internal medicine, Cancer registries, Penile cancers, Survival trends, Testicular, Survival trend, medicine, business, Penis, Testicular cancer
Abstract: Background We provide updated estimates of survival and survival trends of male genital tumours (prostate, testicular and penis cancers), in Europe and across European areas. Methods The complete approach was used to obtain relative survival estimates for patients diagnosed in 2000–2007, and followed up through 2008 in 29 countries. Data came from 87 cancer registries (CRs) for prostate tumours and from 86 CRs for testis and penis tumours. Relative survival time trends in 1999–2007 were estimated by the period approach. Data came from 49 CRs in 25 countries. Results We analysed 1,021,275 male genital cancer cases. Five-year relative survival was high and decreased with increasing age for all tumours considered. We found limited variation in survival between European regions with Eastern Europe countries having lower survival than the others. Survival for penile cancer patients did not improve from 1999 to 2007. Survival for testicular cancer patients remained stable at high levels since 1999. Survival for prostate cancer patients increased over time. Conclusions Treatment standardisation and centralisation for very rare diseases such as penile cancers or advanced testicular tumours should be supported. The high survival of testicular cancer makes long-term monitoring of testicular cancer survivors necessary and CRs can be an important resource. Prostate cancer patients’ survival must be interpreted considering incidence and mortality data. The follow-up of the European Randomised Study of Screening for Prostate Cancer should continue to clarify the impact of screening on prostate cancer mortality together with population based studies including information on stage and treatments.
Published: 2015
Full Text: View/download PDF

15. The EUROCARE-5 study on cancer survival in Europe 1999-2007: Database, quality checks and statistical analysis methods

Author: Silvia Rossi, Paolo Baili, Riccardo Capocaccia, Massimiliano Caldora, Eugenio Carrani, Pamela Minicozzi, Daniela Pierannunzio, Mariano Santaquilani, Annalisa Trama, Claudia Allemani, Aurelien Belot, Carlotta Buzzoni, Matthias Lorez, Roberta De Angelis, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, A. Mazzei, S. Ferretti, E. Crocetti, G. Manneschi, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, A. Zucchetto, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, M. Natali, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, M. Zarcone, F. Vitale, R. Cusimano, M. Michiara, R. Tumino, P. Giorgi Rossi, M. Vicentini, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, A. Rocca, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Tognazzo, S. Pildava, G. Smailyte, N. Calleja, R. Micallef, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, K. Kepska, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, L. Antunes, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, A. Mateos, M. Errezola, N. Larrañaga, A. Torrella-Ramos, J.M. Díaz García, A.I. Marcos-Navarro, R. Marcos-Gragera, L. Vilardell, M.J. Sanchez, E. Molina, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, V. Ho, S. Siesling, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, D. Fitzpatrick, D.H. Brewster, D.W. Huws, C. White, R. Otter, Rossi S., Baili P., Capocaccia R., Caldora M., Carrani E., Minicozzi P., Pierannunzio D., Santaquilani M., Trama A., Allemani C., Belot A., Buzzoni C., Lorez M., De Angelis R., Zielonke N., Oberaigner W., Van Eycken E., Henau K., Valerianova Z., Dimitrova N., Sekerija M., Zvolsky M., Dus?ek L., Storm H., Engholm G., Magi M., Aareleid T., Malila N., Seppa K., Velten M., Troussard X., Bouvier V., Launoy G., Guizard A.V., Faivre J., Bouvier A.M., Arveux P., Maynadie M., Woronoff A.S., Robaszkiewicz M., Baldi I., Monnereau A., Tretarre B., Bossard N., Colonna M., Molinie F., Bara S., Schvartz C., Lapotre-Ledoux B., Grosclaude P., Meyer M., Stabenow R., Luttmann S., Eberle A., Brenner H., Nennecke A., Engel J., Schubert-Fritschle G., Kieschke J., Heidrich J., Holleczek B., Katalinic A., Jonasson J.G., Tryggvadottir L., Comber H., Mazzoleni G., Bulatko A., Giacomin A., Sutera Sardo A., Mazzei A., Ferretti S., Crocetti E., Manneschi G., Gatta G., Sant M., Amash H., Amati C., Berrino F., Bonfarnuzzo S., Botta L., Di Salvo F., Foschi R., Margutti C., Meneghini E., Serraino D., Zucchetto A., Francisci S., Mallone S., Roazzi P., Tavilla A., Pannozzo F., Natali M., Bonelli L., Vercelli M., Gennaro V., Ricci P., Autelitano M., Randi G., Ponz De Leon M., Marchesi C., Cirilli C., Fusco M., Vitale M.F., Usala M., Traina A., Zarcone M., Vitale F., Cusimano R., Michiara M., Tumino R., Giorgi Rossi P., Vicentini M., Falcini F., Iannelli A., Sechi O., Cesaraccio R., Piffer S., Madeddu A., Tisano F., Maspero S., Fanetti A.C., Zanetti R., Rosso S., Candela P., Scuderi T., Stracci F., Rocca A., Tagliabue G., Contiero P., Dei Tos A.P., Tognazzo S., Pildava S., Smailyte G., Calleja N., Micallef R., Johannesen T.B., Rachtan J., Gozdz S., Me zyk R., Baszczyk J., Kepska K., Bielska-Lasota M., Forjaz de Lacerda G., Bento M.J., Antunes L., Miranda A., Mayer-da-Silva A., Nicula F., Coza D., Safaei Diba C., Primic-Zakelj M., Almar E., Mateos A., Errezola M., Larranaga N., Torrella-Ramos A., Diaz Garcia J.M., Marcos-Navarro A.I., Marcos-Gragera R., Vilardell L., Sanchez M.J., Molina E., Navarro C., Chirlaque M.D., Moreno-Iribas C., Ardanaz E., Galceran J., Carulla M., Lambe M., Khan S., Mousavi M., Bouchardy C., Usel M., Ess S.M., Frick H., Herrmann C., Bordoni A., Spitale A., Konzelmann I., Ho V., Siesling S., Coleman M., Rachet B., Verne J., Easey N., Lawrence G., Moran T., Rashbass J., Roche M., Wilkinson J., Gavin A., Fitzpatrick D., Brewster D.H., Huws D.W., White C., and Otter R.
Subjects: Cancer Research, Survival, Population, Socio-culturale, Population-based registries, Population-based registrie, Quality checks, Cancer, EUROCARE, Europe, Oncology, Medicine, education, education.field_of_study, Relative survival, business.industry, Population size, Comparability, Percentage point, medicine.disease, Quality check, Data quality, Cohort, business, Demography
Abstract: Background Since 25 years the EUROCARE study monitors the survival of cancer patients in Europe through centralised collection, quality check and statistical analysis of population-based cancer registries (CRs) data. The European population covered by the study increased remarkably in the latest round. The study design and statistical methods were also changed to improve timeliness and comparability of survival estimates. To interpret the EUROCARE-5 results on adult cancer patients better here we assess the impact of these changes on data quality and on survival comparisons. Methods In EUROCARE-5 the survival differences by area were studied applying the complete cohort approach to data on nearly nine million cancer patients diagnosed in 2000–2007 and followed up to 2008. Survival time trends were analysed applying the period approach to data on about 10 million cancer cases diagnosed from 1995 to 2007 and followed up to 2008. Differently from EUROCARE-4, multiple primary cancers were included and relative survival was estimated with the Ederer II method. Results EUROCARE-5 covered a population of 232 million resident persons, corresponding to 50% of the 29 participating countries. The population coverage increased particularly in Eastern Europe. Cases identified from death certificate only (DCO) were on average 2.9%, range 0–12%. Microscopically confirmed cases amounted to over 85% in most CRs. Compared to previous methods, including multiple cancers and using the Ederer II estimator reduced survival estimates by 0.4 and 0.3 absolute percentage points, on average. Conclusions The increased population size and registration coverage of the EUROCARE-5 study ensures more robust and comparable estimates across European countries. This enlargement did not impact on data quality, which was generally satisfactory. Estimates may be slightly inflated in countries with high or null DCO proportions, especially for poor prognosis cancers. The updated methods improved the comparability of survival estimates between recently and long-term established registries and reduced biases due to informative censoring.
Published: 2015

16. Completeness and timeliness: Cancer registries could/should improve their performance

Author: E. Van Eycken, Lidia Sacchetto, David Robinson, Jaume Galceran, Stefano Ferretti, Irene Schmidtmann, Vesna Zadnik, D. Coza, Stefano Rosso, Laufey Tryggvadottir, Roberto Zanetti, Nerea Larrañaga, F. Binder-Foucard, J.W.W. Coebergh, Andrea Bordoni, and Anna Gavin
Subjects: Completeness, Cancer Research, Time Factors, Cancer registry, Completeness, Timeliness, Flow method, Population, Flow method, Death Certificates, NO, Median latency, Cause of Death, Neoplasms, Medicine, Humans, Registries, education, education.field_of_study, business.industry, Information Dissemination, Data Collection, Incidence, Comparability, Timeliness, Cancer registry, medicine.disease, Quality Improvement, Europe, Oncology, Population Surveillance, Medical emergency, Death certificate, business, Completeness (statistics)
Abstract: Cancer registries must provide complete and reliable incidence information with the shortest possible delay for use in studies such as comparability, clustering, cancer in the elderly and adequacy of cancer surveillance. Methods of varying complexity are available to registries for monitoring completeness and timeliness. We wished to know which methods are currently in use among cancer registries, and to compare the results of our findings to those of a survey carried out in 2006. Methods In the framework of the EUROCOURSE project, and to prepare cancer registries for participation in the ERA-net scheme, we launched a survey on the methods used to assess completeness, and also on the timeliness and methods of dissemination of results by registries. We sent the questionnaire to all general registries (GCRs) and specialised registries (SCRs) active in Europe and within the European Network of Cancer Registries (ENCR). Results With a response rate of 66% among GCRs and 59% among SCRs, we obtained data for analysis from 116 registries with a population coverage of ∼280 million. The most common methods used were comparison of trends (79%) and mortality/incidence ratios (more than 60%). More complex methods were used less commonly: capture–recapture by 30%, flow method by 18% and death certificate notification (DCN) methods with the Ajiki formula by 9%. The median latency for completion of ascertainment of incidence was 18 months. Additional time required for dissemination was of the order of 3–6 months, depending on the method: print or electronic. One fifth (21%) did not publish results for their own registry but only as a contribution to larger national or international data repositories and publications; this introduced a further delay in the availability of data. Conclusions Cancer registries should improve the practice of measuring their completeness regularly and should move from traditional to more quantitative methods. This could also have implications in the timeliness of data publication.
Published: 2013

17. Survival for oesophageal, stomach and small intestine cancers in Europe 1999-2007: results from EUROCARE-5

Author: L.A. Anderson, A. Tavilla, H. Brenner, S. Luttmann, C. Navarro, A.T. Gavin, B. Holleczek, B.T. Johnston, M.B. Cook, F. Bannon, M. Sant, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dusek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, A. Eberle, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, P. Mancuso, S. Ferretti, E. Crocetti, A. Caldarella, G. Gatta, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, L. Dal Maso, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, F. Pannozzo, S. Busco, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, R. Staiti, F. Vitale, B. Ravazzolo, M. Michiara, R. Tumino, P. Giorgi Rossi, E. Di Felice, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, F. Bianconi, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Guzzinati, S. Pildava, G. Smailyte, N. Calleja, D. Agius, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, M. Bebenek, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, C. Castro, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, C. Ramírez, M. Errezola, J. Bidaurrazaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, R. Marcos-Gragera, A. Izquierdo Font, M.J. Sanchez, D.Y.L. Chang, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, R. Verhoeven, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, C. Donnelly, D.H. Brewster, D.W. Huws, C. White, and R. Otter
Subjects: medicine.medical_specialty, Cancer Research, Survival, Europe, Oesophageal, Small intestine, Stomach, Gastroenterology, Article, SDG 3 - Good Health and Well-being, Internal medicine, Medicine, In patient, Stomach cancer, Relative survival, business.industry, Cancer, Patient survival, medicine.disease, medicine.anatomical_structure, Oncology, business, Small intestine cancer, Demography
Abstract: Background European regional variation in cancer survival was reported in the EUROCARE-4 study for patients diagnosed in 1995–1999. Relative survival (RS) estimates are here updated for patients diagnosed with cancer of the oesophagus, stomach and small intestine from 2000 to 2007. Trends in RS from 1999–2001 to 2005–2007 are presented to monitor and discuss improvements in patient survival in Europe. Materials and methods EUROCARE-5 data from 29 countries (87 cancer registries) were used to investigate 1- and 5-year RS. Using registry-specific life-tables stratified by age, gender and calendar year, age-standardised ‘complete analysis’ RS estimates by country and region were calculated for Northern, Southern, Eastern and Central Europe, and for Ireland and United Kingdom (UK). Survival trends of patients in periods 1999–2001, 2002–2004 and 2005–2007 were investigated using the ‘period’ RS approach. We computed the 5-year RS conditional on surviving the first year (5-year conditional survival), as the ratio of age-standardised 5-year RS to 1-year RS. Results Oesophageal cancer 1- and 5-year RS (40% and 12%, respectively) remained poor in Europe. Patient survival was worst in Eastern (8%), Northern (11%) and Southern Europe (10%). Europe-wide, there was a 3% improvement in oesophageal cancer 5-year survival by 2005–2007, with Ireland and the UK (3%), and Central Europe (4%) showing large improvements. Europe-wide, stomach cancer 5-year RS was 25%. Ireland and UK (17%) and Eastern Europe (19%) had the poorest 5-year patient survival. Southern Europe had the best 5-year survival (30%), though only showing an improvement of 2% by 2005–2007. Small intestine cancer 5-year RS for Europe was 48%, with Central Europe having the best (54%), and Ireland and UK the poorest (37%). Five-year patient survival improvement for Europe was 8% by 2005–2007, with Central, Southern and Eastern Europe showing the greatest increases (⩾9%). Conclusions Survival for these cancer sites, particularly oesophageal cancer, remains poor in Europe with wide variation. Further investigation into the wide variation, including analysis by histology and anatomical sub-site, will yield insights to better monitor and explain the improvements in survival observed over time.
Full Text: View/download PDF

18. Time Trends Analysis of Cervical Cancer Incidence in Cluj County, Romania, Using Data from a Population-Based Cancer Registry.

Author: Ignat RM, Coza D, Ignat P, Badea RI, and Șuteu O
Subjects: Female, Humans, Incidence, Registries, Romania epidemiology, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms epidemiology
Abstract: (1) Background: Romania has one of the highest cervical cancer incidence rates in Europe. In Cluj County, the first screening program was initiated in 1998. We aimed to investigate the time trends of cervical cancer incidence in women from Cluj County and to evaluate the data quality at the Cancer Registry. (2) Methods: We calculated time trends of standardized incidence rates in the period 1998-2014 and the Annual Percent Change (APC%). To assess data quality, we used the indicators: mortality/incidence ratio (M/I), percentage of cases declared only at death (DOD%), and percentage of cases with pathological confirmation (PC%). (3) Results: The standardized incidence rate increased steadily, from 23.74 cases/100,000 in 1998, to 32/100,000 in 2014, with an APC% of 2.49% ( p < 0.05). The rise in incidence affected both squamous cell carcinoma (APC% 2.49%) ( p < 0.05) and cervical adenocarcinoma (APC% 10.54%) ( p < 0.05). The M/I ratio was 0.29, DOD% 2.66%, and MC% 94.8%. The last two parameters are within the silver standard concerning data quality. (4) Conclusions. Our study revealed an ascending trend of cervical cancer incidence, more consistent for adenocarcinoma, in the context of a newly introduced screening program and partially due to the improvement of the quality of case reporting at the Cancer Registry from Cluj.
Published: 2021
Full Text: View/download PDF

19. Birth seasonality of childhood central nervous system tumors: Analysis of primary data from 16 Southern-Eastern European population-based registries.

Author: Karalexi MA, Dessypris N, Georgakis MK, Ryzhov A, Jakab Z, Zborovskaya A, Dimitrova N, Zivkovic S, Trojanowski M, Sekerija M, Antunes L, Zagar T, Eser S, Bastos J, Demetriou A, Agius D, Coza D, Gheorghiu R, Kantzanou M, Ntzani EE, and Petridou ET
Subjects: Adolescent, Astrocytoma epidemiology, Astrocytoma pathology, Central Nervous System Neoplasms pathology, Child, Child, Preschool, Europe epidemiology, Europe, Eastern epidemiology, Female, Humans, Incidence, Infant, Infant, Newborn, Male, Neoplasms, Germ Cell and Embryonal epidemiology, Neoplasms, Germ Cell and Embryonal pathology, Parturition, Risk, Seasons, Central Nervous System Neoplasms epidemiology, Registries statistics & numerical data
Abstract: Season of birth, a surrogate of seasonal variation of environmental exposures, has been associated with increased risk of several cancers. In the context of a Southern-Eastern Europe (SEE) consortium, we explored the potential association of birth seasonality with childhood (0-14 years) central nervous system (CNS) tumors. Primary CNS tumor cases (n = 6,014) were retrieved from 16 population-based SEE registries (1983-2015). Poisson regression and meta-analyses on birth season were performed in nine countries with available live birth data (n = 4,987). Subanalyses by birth month, age, gender and principal histology were also conducted. Children born during winter were at a slightly increased risk of developing a CNS tumor overall [incidence rate ratio (IRR): 1.06, 95% confidence intervals (CI): 0.99-1.14], and of embryonal histology specifically (IRR: 1.13, 95% CI: 1.01-1.27). The winter peak of embryonal tumors was higher among boys (IRR: 1.24, 95% CI: 1.05-1.46), especially during the first 4 years of life (IRR: 1.33, 95% CI: 1.03-1.71). In contrast, boys <5 years born during summer seemed to be at a lower risk of embryonal tumors (IRR: 0.73, 95% CI: 0.54-0.99). A clustering of astrocytomas was also found among girls (0-14 years) born during spring (IRR: 1.23, 95% CI: 1.03-1.46). Although the present exploratory results are by no means definitive, they provide some indications for age-, gender- and histology-related seasonal variations of CNS tumors. Expansion of registration and linkage with cytogenetic reports could refine if birth seasonality is causally associated with CNS tumors and shed light into the complex pathophysiology of this lethal disease., (© 2020 UICC.)
Published: 2020
Full Text: View/download PDF

20. Development of paediatric non-stage prognosticator guidelines for population-based cancer registries and updates to the 2014 Toronto Paediatric Cancer Stage Guidelines.

Author: Gupta S, Aitken J, Bartels U, Bhakta N, Bucurenci M, Brierley JD, De Camargo B, Chokunonga E, Clymer J, Coza D, Fraser C, Fuentes-Alabi S, Gatta G, Gross T, Jakab Z, Kohler B, Kutluk T, Moreno F, Nakata K, Nur S, Parkin DM, Penberthy L, Pole J, Poynter JN, Pritchard-Jones K, Ramirez O, Renner L, Steliarova-Foucher E, Sullivan M, Swaminathan R, Van Eycken L, Vora T, and Frazier AL
Subjects: Child, Delivery of Health Care, Humans, Neoplasm Staging, Neoplasms epidemiology, Registries, Guidelines as Topic standards, Neoplasms therapy, Pediatrics trends, Prognosis
Abstract: Population-based cancer registries (PBCRs) generate measures of cancer incidence and survival that are essential for cancer surveillance, research, and cancer control strategies. In 2014, the Toronto Paediatric Cancer Stage Guidelines were developed to standardise how PBCRs collect data on the stage at diagnosis for childhood cancer cases. These guidelines have been implemented in multiple jurisdictions worldwide to facilitate international comparative studies of incidence and outcome. Robust stratification by risk also requires data on key non-stage prognosticators (NSPs). Key experts and stakeholders used a modified Delphi approach to establish principles guiding paediatric cancer NSP data collection. With the use of these principles, recommendations were made on which NSPs should be collected for the major malignancies in children. The 2014 Toronto Stage Guidelines were also reviewed and updated where necessary. Wide adoption of the resultant Paediatric NSP Guidelines and updated Toronto Stage Guidelines will enhance the harmonisation and use of childhood cancer data provided by PBCRs., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
Published: 2020
Full Text: View/download PDF

21. Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania.

Author: Şuteu O, Blaga ML, Nygård M, Leinonen MK, Nicula F, Păiş R, Coza D, Cadariu PA, Melnic A, Andreassen T, Hashim D, and Weiderpass E
Subjects: Adult, Alphapapillomavirus genetics, Alphapapillomavirus isolation & purification, Cervix Uteri cytology, Cervix Uteri pathology, Cervix Uteri virology, Cross-Sectional Studies, DNA, Viral isolation & purification, Early Detection of Cancer methods, Feasibility Studies, Female, Humans, Mass Screening methods, Middle Aged, Molecular Diagnostic Techniques statistics & numerical data, Papanicolaou Test statistics & numerical data, Papillomavirus Infections diagnosis, Papillomavirus Infections pathology, Papillomavirus Infections virology, Pilot Projects, Prevalence, Romania epidemiology, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms virology, Vaginal Smears statistics & numerical data, Uterine Cervical Dysplasia diagnosis, Uterine Cervical Dysplasia pathology, Uterine Cervical Dysplasia virology, Early Detection of Cancer statistics & numerical data, Mass Screening statistics & numerical data, Papillomavirus Infections epidemiology, Uterine Cervical Neoplasms epidemiology, Uterine Cervical Dysplasia epidemiology
Abstract: Using data from a pilot study conducted in North-Western Romania, we aimed to estimate the prevalence of abnormal cytology and positive high-risk human papillomavirus (hr-HPV) test results in an ethnically diverse screening population and to assess the agreement between cytology and hr-HPV testing to evaluate the feasibility of integrating the latter as a primary test in the national cervical cancer screening program. The cross-sectional pilot study included Roma women, other ethnic minorities, and women in rural remote areas. Samples were taken for liquid-based cytology and hr-HPV testing (Hybrid Capture 2 DNA test) by a mobile health unit. The prevalence of positive screening results and the agreement between cytology and hr-HPV testing were estimated by κ coefficient. A total of 1019 women were included in the study. The population prevalence of positive screening results was similar for both tests (12%). The prevalence of abnormal cytology increased with increasing age, whereas the prevalence of positive hr-HPV test showed a bimodal age pattern. Substantial differences in the prevalence of abnormal cytology were found by ethnicity, with highest prevalence in Romanian women (14%), followed by Roma women (6%) and women of other ethnicities (5%) (P = 0.002). Similar ethnic differences in the prevalence of positive hr-HPV test were not observed. The overall agreement of positive screening results between the two methods was fair (κ = 0.25; 95% confidence interval = 0.18-0.30, P < 0.001) and ranged from poor to substantial depending on the age group. The prevalence of abnormal cytology result was high and similar to the prevalence of positive hr-HPV test result, which could allow for the implementation of hr-HPV testing as a primary test in the cervical cancer screening program in Romania.
Published: 2020
Full Text: View/download PDF

22. Survival and mortality rates of Wilms tumour in Southern and Eastern European countries: Socioeconomic differentials compared with the United States of America.

Author: Doganis D, Panagopoulou P, Tragiannidis A, Vichos T, Moschovi M, Polychronopoulou S, Rigatou E, Papakonstantinou E, Stiakaki E, Dana H, Bouka P, Antunes L, Bastos J, Coza D, Demetriou A, Agius D, Eser S, Ryzhov A, Sekerija M, Trojanowski M, Zagar T, Zborovskaya A, Perisic SZ, Strantzia K, Dessypris N, Psaltopoulou T, and Petridou ET
Subjects: Adolescent, Child, Child, Preschool, Europe epidemiology, Female, Humans, Infant, Kaplan-Meier Estimate, Male, Survival Rate, United States epidemiology, Wilms Tumor epidemiology, Registries statistics & numerical data, Socioeconomic Factors, Wilms Tumor mortality
Abstract: Background: Despite recent therapeutic advancements, Wilms tumour (WT) presents remarkable survival variations. We explored mortality and survival patterns for children (0-14 years) with WT in 12 Southern and Eastern European (SEE) countries in comparison with the United States of America (USA)., Methods: A total of 3966 WT cases (0-14 years) were registered by a network of SEE childhood cancer registries (N:1723) during available registration periods circa 1990-2016 and surveillance, epidemiology, and end results program (SEER) (N:2243; 1990-2012); mortality data were provided by the respective national statistical services. Kaplan-Meier curves and Cox proportional hazards models were used to assess the role of age, sex, year of diagnosis, urbanisation and Human Development Index (HDI) on overall survival (OS)., Results: Persisting regional variations shape an overall 78% 5-year OS in the participating SEE countries, lagging behind the USA figure (92%, p=0.001) and also reflected by higher SEE mortality rates. Worth mentioning is the gradually escalating OS in SEE (hazard ratio [HR] 5-year increment :0.67, 95% confidence interval [CI]:0.60, 0.75) vs. a non-significant 10% improvement in the SEER data, which had a high starting value. OS differentials [two-fold less favourable among children aged 10-14 years, boys and those living in rural SEE areas (HR:1.37; CI:1.10-1.71) or countries with inferior HDI (2-3-fold)] were minimal in the USA., Conclusions: Children with WT residing in SEE countries do not equally enjoy the substantial survival gains, especially for those living in rural areas and in lower HDI countries. Noteworthy are steep and sizeable survival gains in SEE along with the newly presented Greek data pointing to achievable survival goals in SEE despite the financial crisis., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
Published: 2018
Full Text: View/download PDF

23. Childhood nephroblastoma in Southern and Eastern Europe and the US: Incidence variations and temporal trends by human development index.

Author: Doganis D, Panagopoulou P, Tragiannidis A, Georgakis MK, Moschovi M, Polychronopoulou S, Rigatou E, Papakonstantinou E, Stiakaki E, Dana H, Bouka E, Antunes L, Bastos J, Coza D, Demetriou A, Agius D, Eser S, Ryzhov A, Sekerija M, Trojanowski M, Zagar T, Zborovskaya A, Perisic SZ, Stefanaki K, Dessypris N, and Petridou ET
Subjects: Adolescent, Child, Child, Preschool, Europe epidemiology, Europe, Eastern epidemiology, Female, Humans, Incidence, Infant, Male, SEER Program, United States epidemiology, Registries statistics & numerical data, Wilms Tumor epidemiology
Abstract: Background: Despite advances in the management of nephroblastoma (Wilms' tumor, WT), the etiology of the tumor remains obscure. We aimed to compare nephroblastoma incidence rates and time trends among children (0-14 years) in 12 Southern and Eastern European (SEE) countries and the Surveillance, Epidemiology, and End Results Program (SEER), USA, in relation to the human development index (HDI)., Methods: In total 1776 WT cases were recorded in 13 SEE collaborating registries (circa 1990-2016), whereas data on 2260 cases (1990-2012) were extracted from the SEER database. Age-standardized incidence rates (AIRs) were calculated and correlated with HDI, whereas temporal trends were evaluated using Poisson regression and Joinpoint analyses., Results: The overall SEE AIR (9.2/10 6 ) was marginally higher than that of the SEER (8.3/10 6 ), whereas significant differences were noted among the 13 SEE registries which comprised mainly Caucasian populations. A statistically significant temporal increase in incidence was noted only in Belarus. Most cases (∼75%) were diagnosed before the fifth year of life, with rates steadily declining thereafter; median age at diagnosis was similar in SEE countries and SEER. A slight male preponderance in the first year of life (male:female = 1.1) was followed by a female preponderance in the older age groups (male:female = 0.7). Lastly, a statistically significant positive association between higher HDI and increasing nephroblastoma incidence was noted (regression coefficient: +3.25, 95%CI: +1.35, +5.15)., Conclusions: Variations in incidence and time trends across the examined registries, changing male-to-female patterns with advancement in age, and positive associations with the HDI imply a plausible role for environmental and genetic factors in disease etiology, and these need to be explored further., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
Published: 2018
Full Text: View/download PDF

24. Persisting inequalities in survival patterns of childhood neuroblastoma in Southern and Eastern Europe and the effect of socio-economic development compared with those of the US.

Author: Panagopoulou P, Georgakis MK, Baka M, Moschovi M, Papadakis V, Polychronopoulou S, Kourti M, Hatzipantelis E, Stiakaki E, Dana H, Tragiannidis A, Bouka E, Antunes L, Bastos J, Coza D, Demetriou A, Agius D, Eser S, Gheorghiu R, Šekerija M, Trojanowski M, Žagar T, Zborovskaya A, Ryzhov A, Dessypris N, Morgenstern D, and Petridou ET
Subjects: Adolescent, Age of Onset, Child, Child, Preschool, Europe epidemiology, Female, Humans, Incidence, Infant, Infant, Newborn, Male, Neuroblastoma diagnosis, Risk Factors, SEER Program, Time Factors, Treatment Outcome, United States epidemiology, Cancer Survivors, Health Status Disparities, Healthcare Disparities trends, Human Development, Neuroblastoma mortality, Neuroblastoma therapy, Social Determinants of Health trends, Socioeconomic Factors, Survival Rate trends
Abstract: Aim: Neuroblastoma outcomes vary with disease characteristics, healthcare delivery and socio-economic indicators. We assessed survival patterns and prognostic factors for patients with neuroblastoma in 11 Southern and Eastern European (SEE) countries versus those in the US, including-for the first time-the Nationwide Registry for Childhood Hematological Malignancies and Solid Tumours (NARECHEM-ST)/Greece., Methods: Overall survival (OS) was calculated in 13 collaborating SEE childhood cancer registries (1829 cases, ∼1990-2016) and Surveillance, Epidemiology, and End Results (SEER), US (3072 cases, 1990-2012); Kaplan-Meier curves were used along with multivariable Cox regression models assessing the effect of age, gender, primary tumour site, histology, Human Development Index (HDI) and place of residence (urban/rural) on survival., Results: The 5-year OS rates varied widely among the SEE countries (Ukraine: 45%, Poland: 81%) with the overall SEE rate (59%) being significantly lower than in SEER (77%; p < 0.001). In the common registration period within SEE (2000-2008), no temporal trend was noted as opposed to a significant increase in SEER. Age >12 months (hazard ratio [HR]: 2.8-4.7 in subsequent age groups), male gender (HR: 1.1), residence in rural areas (HR: 1.3), living in high (HR: 2.2) or medium (HR: 2.4) HDI countries and specific primary tumour location were associated with worse outcome; conversely, ganglioneuroblastoma subtype (HR: 0.28) was associated with higher survival rate., Conclusions: Allowing for the disease profile, children with neuroblastoma in SEE, especially those in rural areas and lower HDI countries, fare worse than patients in the US, mainly during the early years after diagnosis; this may be attributed to presumably modifiable socio-economic and healthcare system performance differentials warranting further research., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
Published: 2018
Full Text: View/download PDF

25. Neuroblastoma among children in Southern and Eastern European cancer registries: Variations in incidence and temporal trends compared to US.

Author: Georgakis MK, Dessypris N, Baka M, Moschovi M, Papadakis V, Polychronopoulou S, Kourti M, Hatzipantelis E, Stiakaki E, Dana H, Bouka E, Antunes L, Bastos J, Coza D, Demetriou A, Agius D, Eser S, Gheorghiu R, Sekerija M, Trojanowski M, Zagar T, Zborovskaya A, Ryzhov A, Tragiannidis A, Panagopoulou P, Steliarova-Foucher E, and Petridou ET
Subjects: Adolescent, Child, Child, Preschool, Europe epidemiology, Europe, Eastern epidemiology, Female, Humans, Incidence, Infant, Infant, Newborn, Male, Registries, SEER Program, United States epidemiology, Neuroblastoma epidemiology
Abstract: Neuroblastoma comprises the most common neoplasm during infancy (first year of life). Our study describes incidence of neuroblastoma in Southern-Eastern Europe (SEE), including - for the first time - the Nationwide Registry for Childhood Hematological Malignancies and Solid Tumors (NARECHEM-ST)/Greece, compared to the US population, while controlling for human development index (HDI). Age-adjusted incidence rates (AIR) were calculated for 1,859 childhood (0-14 years) neuroblastoma cases, retrieved from 13 collaborating SEE registries (1990-2016), and were compared to those of SEER/US (N = 3,166; 1990-2012); temporal trends were assessed using Poisson regression and Joinpoint analyses. The overall AIR was significantly lower in SEE (10.1/million) compared to SEER (11.7 per million); the difference was maximum during infancy (43.7 vs. 53.3 per million, respectively), when approximately one-third of cases were diagnosed. Incidence rates of neuroblastoma at ages <1 and 1-4 years were positively associated with HDI, whereas lower median age at diagnosis was correlated with higher overall AIR. Distribution of primary site and histology was similar in SEE and SEER. Neuroblastoma was slightly more common among males compared to females (male-to-female ratio: 1.1), mainly among SEE infants. Incidence trends decreased in infants in Slovenia, Cyprus and SEER and increased in Ukraine and Belarus. The lower incidence in SEE compared to SEER, especially in infants living in low HDI countries possibly indicates a lower level of overdiagnosis in SEE. Hence, increases in incidence rates in infancy noted in some subpopulations should be carefully monitored to avoid the unnecessary costs health impacts of tumors that could potentially spontaneously regress., (© 2017 UICC.)
Published: 2018
Full Text: View/download PDF

26. Trends in incidence of thick, thin and in situ melanoma in Europe.

Author: Sacchetto L, Zanetti R, Comber H, Bouchardy C, Brewster DH, Broganelli P, Chirlaque MD, Coza D, Galceran J, Gavin A, Hackl M, Katalinic A, Larønningen S, Louwman MWJ, Morgan E, Robsahm TE, Sanchez MJ, Tryggvadóttir L, Tumino R, Van Eycken E, Vernon S, Zadnik V, and Rosso S
Subjects: Age Distribution, Databases, Factual, Europe epidemiology, Female, Humans, Incidence, Male, Melanoma mortality, Middle Aged, Mortality trends, Neoplasm Invasiveness, Registries, Sex Distribution, Skin Neoplasms mortality, Time Factors, Melanoma epidemiology, Melanoma pathology, Skin Neoplasms epidemiology, Skin Neoplasms pathology
Abstract: Background: We analysed trends in incidence for in situ and invasive melanoma in some European countries during the period 1995-2012, stratifying for lesion thickness., Material and Methods: Individual anonymised data from population-based European cancer registries (CRs) were collected and combined in a common database, including information on age, sex, year of diagnosis, histological type, tumour location, behaviour (invasive, in situ) and lesion thickness. Mortality data were retrieved from the publicly available World Health Organization database., Results: Our database covered a population of over 117 million inhabitants and included about 415,000 skin lesions, recorded by 18 European CRs (7 of them with national coverage). During the 1995-2012 period, we observed a statistically significant increase in incidence for both invasive (average annual percent change (AAPC) 4.0% men; 3.0% women) and in situ (AAPC 7.7% men; 6.2% women) cases., Discussion: The increase in invasive lesions seemed mainly driven by thin melanomas (AAPC 10% men; 8.3% women). The incidence of thick melanomas also increased, although more slowly in recent years. Correction for lesions of unknown thickness enhanced the differences between thin and thick cases and flattened the trends. Incidence trends varied considerably across registries, but only Netherlands presented a marked increase above the boundaries of a funnel plot that weighted estimates by their precision. Mortality from invasive melanoma has continued to increase in Norway, Iceland (but only for elder people), the Netherlands and Slovenia., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
Published: 2018
Full Text: View/download PDF

27. Mortality and survival patterns of childhood lymphomas: geographic and age-specific patterns in Southern-Eastern European and SEER/US registration data.

Author: Karalexi MA, Georgakis MK, Dessypris N, Ryzhov A, Zborovskaya A, Dimitrova N, Zivkovic S, Eser S, Antunes L, Sekerija M, Zagar T, Bastos J, Demetriou A, Agius D, Florea M, Coza D, Bouka E, Dana H, Hatzipantelis E, Kourti M, Moschovi M, Polychronopoulou S, Stiakaki E, Pourtsidis A, and Petridou ET
Subjects: Adolescent, Age Factors, Child, Child, Preschool, Europe epidemiology, Female, Humans, Infant, Infant, Newborn, Kaplan-Meier Estimate, Lymphoma epidemiology, Male, Population Surveillance, Proportional Hazards Models, Registries, SEER Program, United States epidemiology, Lymphoma mortality
Abstract: Childhood (0-14 years) lymphomas, nowadays, present a highly curable malignancy compared with other types of cancer. We used readily available cancer registration data to assess mortality and survival disparities among children residing in Southern-Eastern European (SEE) countries and those in the United States. Average age-standardized mortality rates and time trends of Hodgkin (HL) and non-Hodgkin (NHL; including Burkitt [BL]) lymphomas in 14 SEE cancer registries (1990-2014) and the Surveillance, Epidemiology, and End Results Program (SEER, United States; 1990-2012) were calculated. Survival patterns in a total of 8918 cases distinguishing also BL were assessed through Kaplan-Meier curves and multivariate Cox regression models. Variable, rather decreasing, mortality trends were noted among SEE. Rates were overall higher than that in SEER (1.02/10 6 ), which presented a sizeable (-4.8%, P = .0001) annual change. Additionally, remarkable survival improvements were manifested in SEER (10 years: 96%, 86%, and 90% for HL, NHL, and BL, respectively), whereas diverse, still lower, rates were noted in SEE. Non-HL was associated with a poorer outcome and an amphi-directional age-specific pattern; specifically, prognosis was inferior in children younger than 5 years than in those who are 10 to 14 years old from SEE (hazard ratio 1.58, 95% confidence interval 1.28-1.96) and superior in children who are 5 to 9 years old from SEER/United States (hazard ratio 0.63, 95% confidence interval 0.46-0.88) than in those who are 10 to 14 years old. In conclusion, higher SEE lymphoma mortality rates than those in SEER, but overall decreasing trends, were found. Despite significant survival gains among developed countries, there are still substantial geographic, disease subtype-specific, and age-specific outcome disparities pointing to persisting gaps in the implementation of new treatment modalities and indicating further research needs., (Copyright © 2016 John Wiley & Sons, Ltd.)
Published: 2017
Full Text: View/download PDF

28. Malignant central nervous system tumors among adolescents and young adults (15-39 years old) in 14 Southern-Eastern European registries and the US Surveillance, Epidemiology, and End Results program: Mortality and survival patterns.

Author: Georgakis MK, Papathoma P, Ryzhov A, Zivkovic-Perisic S, Eser S, Taraszkiewicz Ł, Sekerija M, Žagar T, Antunes L, Zborovskaya A, Bastos J, Florea M, Coza D, Demetriou A, Agius D, Strahinja RM, Themistocleous M, Tolia M, Tzanis S, Alexiou GA, Papanikolaou PG, Nomikos P, Kantzanou M, Dessypris N, Pourtsidis A, and Petridou ET
Subjects: Adolescent, Adult, Central Nervous System Neoplasms epidemiology, Europe epidemiology, Europe, Eastern epidemiology, Female, Humans, Male, Registries, SEER Program, Survival Rate, United States epidemiology, Young Adult, Central Nervous System Neoplasms mortality
Abstract: Background: Unique features and worse outcomes have been reported for cancers among adolescents and young adults (AYAs; 15-39 years old). The aim of this study was to explore the mortality and survival patterns of malignant central nervous system (CNS) tumors among AYAs in Southern-Eastern Europe (SEE) in comparison with the US Surveillance, Epidemiology, and End Results (SEER) program., Methods: Malignant CNS tumors diagnosed in AYAs during the period spanning 1990-2014 were retrieved from 14 population-based cancer registries in the SEE region (n = 11,438). Age-adjusted mortality rates were calculated and survival patterns were evaluated via Kaplan-Meier curves and Cox regression analyses, and they were compared with respective 1990-2012 figures from SEER (n = 13,573)., Results: Mortality rates in SEE (range, 11.9-18.5 deaths per million) were higher overall than the SEER rate (9.4 deaths per million), with decreasing trends in both regions. Survival rates increased during a comparable period (2001-2009) in SEE and SEER. The 5-year survival rate was considerably lower in the SEE registries (46%) versus SEER (67%), mainly because of the extremely low rates in Ukraine; this finding was consistent across age groups and diagnostic subtypes. The highest 5-year survival rates were recorded for ependymomas (76% in SEE and 92% in SEER), and the worst were recorded for glioblastomas and anaplastic astrocytomas (28% in SEE and 37% in SEER). Advancing age, male sex, and rural residency at diagnosis adversely affected outcomes in both regions., Conclusions: Despite definite survival gains over the last years, the considerable outcome disparities between the less affluent SEE region and the United States for AYAs with malignant CNS tumors point to health care delivery inequalities. No considerable prognostic deficits for CNS tumors are evident for AYAs versus children. Cancer 2017;123:4458-71. © 2017 American Cancer Society., (© 2017 American Cancer Society.)
Published: 2017
Full Text: View/download PDF

29. Central nervous system tumours among adolescents and young adults (15-39 years) in Southern and Eastern Europe: Registration improvements reveal higher incidence rates compared to the US.

Author: Georgakis MK, Panagopoulou P, Papathoma P, Tragiannidis A, Ryzhov A, Zivkovic-Perisic S, Eser S, Taraszkiewicz Ł, Sekerija M, Žagar T, Antunes L, Zborovskaya A, Bastos J, Florea M, Coza D, Demetriou A, Agius D, Strahinja RM, Sfakianos G, Nikas I, Kosmidis S, Razis E, Pourtsidis A, Kantzanou M, Dessypris N, and Petridou ET
Subjects: Adolescent, Adult, Age Distribution, Age of Onset, Astrocytoma diagnosis, Astrocytoma epidemiology, Central Nervous System Neoplasms diagnosis, Data Collection, Europe epidemiology, Female, Humans, Incidence, Male, Regression Analysis, SEER Program, Sex Distribution, Time Factors, United States epidemiology, Young Adult, Central Nervous System Neoplasms epidemiology
Abstract: Aim: To present incidence of central nervous system (CNS) tumours among adolescents and young adults (AYAs; 15-39 years) derived from registries of Southern and Eastern Europe (SEE) in comparison to the Surveillance, Epidemiology and End Results (SEER), US and explore changes due to etiological parameters or registration improvement via evaluating time trends., Methods: Diagnoses of 11,438 incident malignant CNS tumours in AYAs (1990-2014) were retrieved from 14 collaborating SEE cancer registries and 13,573 from the publicly available SEER database (1990-2012). Age-adjusted incidence rates (AIRs) were calculated; Poisson and joinpoint regression analyses were performed for temporal trends., Results: The overall AIR of malignant CNS tumours among AYAs was higher in SEE (28.1/million) compared to SEER (24.7/million). Astrocytomas comprised almost half of the cases in both regions, albeit the higher proportion of unspecified cases in SEE registries (30% versus 2.5% in SEER). Similar were the age and gender distributions across SEE and SEER with a male-to-female ratio of 1.3 and an overall increase of incidence by age. Increasing temporal trends in incidence were documented in four SEE registries (Greater Poland, Portugal North, Turkey-Izmir and Ukraine) versus an annual decrease in Croatia (-2.5%) and a rather stable rate in SEER (-0.3%)., Conclusion: This first report on descriptive epidemiology of AYAs malignant CNS tumours in the SEE area shows higher incidence rates as compared to the United States of America and variable temporal trends that may be linked to registration improvements. Hence, it emphasises the need for optimisation of cancer registration processes, as to enable the in-depth evaluation of the observed patterns by disease subtype., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
Published: 2017
Full Text: View/download PDF

30. Incidence trends and survival of skin melanoma and squamous cell carcinoma in Cluj County, Romania.

Author: Şuteu O, Blaga ML, Nicula F, Şuteu P, Coza O, Achimaş-Cadariu P, and Coza D
Subjects: Adolescent, Adult, Aged, Carcinoma, Squamous Cell diagnosis, Child, Child, Preschool, Female, Humans, Incidence, Infant, Infant, Newborn, Male, Melanoma diagnosis, Middle Aged, Romania epidemiology, Skin Neoplasms diagnosis, Survival Rate trends, Young Adult, Melanoma, Cutaneous Malignant, Carcinoma, Squamous Cell mortality, Melanoma mortality, Registries statistics & numerical data, Skin Neoplasms mortality
Abstract: The aim of this study was to determine the incidence trends of cutaneous melanoma (CM) and squamous cell carcinoma (SCC) in Cluj County, from 1998 to 2011, and the 5-year net survival between 2006 and 2010. Data on all cases of CM and SCC between 1998 and 2011 were obtained from Cluj Cancer Registry. Incidence rates were age standardized by the direct method Age Standardized Incidence Rate (ASIR), using the world standard population. Trends and annual percentage change (APC) of incidence rates were calculated by joinpoint regression analysis. The Pohar-Perme estimator was used to examine the 5-year net survival of cases diagnosed during 2006-2010 and followed up until December 2015. A total of 580 cases of CM and 397 cases of SCC were reported. During 1998-2011, the ASIR of CM increased significantly by 7.8% APC in male patients and by 7.42% APC in female patients, and the ASIR for SCC increased by 9.40% APC in male patients. In female patients, the incidence of SCC increased by 12.65% APC during 2002-2011. The 5-year net survival during 2006-2010 was 0.64 in men and 0.75 in women for CM and 0.86 and 1.00, respectively, for SCC. Survival rates showed an improving trend during 2006-2010, and were generally lower in men. Survival from both entities decreased with age and was lower in rural areas and in advanced stages in both sexes. This study reveals a rising incidence of cutaneous cancers in concordance with international trends. These data support the important role of primary and secondary prevention of skin cancers, focusing not only on melanoma, due to its lower survival, but also on SCC, in order to reduce their burden.
Published: 2017
Full Text: View/download PDF

31. Non-Hodgkin lymphoma in Romania: a single-centre experience.

Author: Fetica B, Achimas-Cadariu P, Pop B, Dima D, Petrov L, Perry AM, Nathwani BN, Müller-Hermelink HK, Diebold J, MacLennan KA, Fulop A, Blaga ML, Coza D, Nicula FA, Irimie A, and Weisenburger DD
Subjects: Adolescent, Adult, Aged, Aged, 80 and over, Child, Female, Humans, Lymphoma, Non-Hodgkin mortality, Male, Middle Aged, Registries, Romania epidemiology, Lymphoma, Non-Hodgkin epidemiology
Abstract: Epidemiologic studies of non-Hodgkin lymphoma (NHL) in Eastern Europe are scarce in the literature. We report the experience of the "Ion Chiricuta" Institute of Oncology in Cluj-Napoca (IOCN), Romania, in the diagnosis and outcome of patients with NHL. We studied 184 consecutive NHL patients diagnosed in the Pathology Department of IOCN during the years 2004-2006. We also obtained epidemiological data from the Northwestern (NW) Cancer Registry. In the IOCN series, the most common lymphoma subtype was diffuse large B-cell lymphoma (43.5%), followed by the chronic lymphocytic leukaemia/small lymphocytic lymphoma (21.2%). T-cell lymphomas represented a small proportion (8.2%). The median age of the patients was 57 years, with a male-to-female ratio of 0.94. Patients with indolent B-cell lymphomas had the best overall survival, whereas those with mantle cell lymphoma had the worst survival. The NW Cancer Registry data showed that the occurrence of NHL in the NW region of Romania was higher in men [world age-standardized incidence rate/100 000 (ASR)-5.9; 95% CI 5.1-6.6] than in women (ASR-4.1; 95% CI 3.5-4.7) with age-standardized male-to-female ratio of 1.44 (p = 0.038). Chronic lymphocytic leukaemia/small lymphocytic lymphoma was the most common NHL in the NW region of Romania, accounting for 43% of all cases, followed by diffuse large B-cell lymphoma (36%). The 5-year, age-standardized cumulative relative survival for NHL in the County of Cluj in NW Romania, for the period of 2006-2010, was 51.4%, with 58.4% survival for men and 43.2% for women. Additional studies of NHL in Eastern Europe are needed. Copyright © 2015 John Wiley & Sons, Ltd., (Copyright © 2015 John Wiley & Sons, Ltd.)
Published: 2017
Full Text: View/download PDF

32. Incidence, time trends and survival patterns of childhood pilocytic astrocytomas in Southern-Eastern Europe and SEER, US.

Author: Georgakis MK, Karalexi MA, Kalogirou EI, Ryzhov A, Zborovskaya A, Dimitrova N, Eser S, Antunes L, Sekerija M, Zagar T, Bastos J, Agius D, Florea M, Coza D, Bouka E, Bourgioti C, Dana H, Hatzipantelis E, Moschovi M, Papadopoulos S, Sfakianos G, Papakonstantinou E, Polychronopoulou S, Sgouros S, Stefanaki K, Stiakaki E, Strantzia K, Zountsas B, Pourtsidis A, Patsouris E, and Petridou ET
Subjects: Adolescent, Age Distribution, Age Factors, Child, Child, Preschool, Europe epidemiology, Europe, Eastern epidemiology, Female, Follow-Up Studies, Humans, Incidence, Infant, Kaplan-Meier Estimate, Male, Proportional Hazards Models, Registries, Time Factors, United States epidemiology, Astrocytoma epidemiology, Astrocytoma mortality, Central Nervous System Neoplasms epidemiology, Central Nervous System Neoplasms mortality
Abstract: Pilocytic astrocytomas (PA) comprise the most common childhood central nervous system (CNS) tumor. Exploiting registry-based data from Southern and Eastern Europe (SEE) and SEER, US, we opted to examine incidence, time trends, survival and tentative outcome disparities of childhood PA by sociodemographic and clinical features. Childhood PA were retrieved from 12 SEE registries (N = 552; 1983-2014) and SEER (N = 2723; 1973-2012). Age-standardized incidence rates (ASR) were estimated and survival was examined via Kaplan-Meier and Cox regression analysis. ASR of childhood PA during 1990-2012 in SEE was 4.2/10 6 , doubling in the USA (8.2/10 6 ). Increasing trends, more prominent during earlier registration years, were recorded in both areas (SEE: +4.1 %, USA: +4.6 %, annually). Cerebellum comprised the most common location, apart from infants in whom supratentorial locations prevailed. Age at diagnosis was 1 year earlier in SEE, whereas 10-year survival was 87 % in SEE and 96 % in SEER, improving over time. Significant outcome predictors were age <1 year at diagnosis diagnosis (hazard ratio, HR [95% confidence intervals]: 3.96, [2.28-6.90]), female gender (HR: 1.38, [1.01-1.88]), residence in SEE (HR: 4.07, [2.95-5.61]) and rural areas (HR: 2.23, [1.53-3.27]), whereas non-cerebellar locations were associated with a 9- to 12-fold increase in risk of death. The first comprehensive overview of childhood PA epidemiology showed survival gains but also outcome discrepancies by geographical region and urbanization pointing to healthcare inequalities. The worse prognosis of infants and, possibly, females merits further consideration, as it might point to treatment adjustment needs, whereas expansion of systematic registration will allow interpretation of incidence variations.
Published: 2017
Full Text: View/download PDF

33. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America.

Author: Karalexi MA, Baka M, Ryzhov A, Zborovskaya A, Dimitrova N, Zivkovic S, Eser S, Antunes L, Sekerija M, Zagar T, Bastos J, Demetriou A, Agius D, Florea M, Coza D, Polychronopoulou S, Stiakaki E, Moschovi M, Hatzipantelis E, Kourti M, Graphakos S, Pombo-de-Oliveira MS, Adami HO, and Petridou ET
Subjects: Adolescent, Age Factors, Child, Child, Preschool, Europe, Europe, Eastern, Female, Humans, Infant, Infant, Newborn, Kaplan-Meier Estimate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myeloid, Acute mortality, Male, Molecular Targeted Therapy, Multivariate Analysis, Precursor Cell Lymphoblastic Leukemia-Lymphoma mortality, Prognosis, Proportional Hazards Models, Protein Kinase Inhibitors therapeutic use, Protein-Tyrosine Kinases antagonists & inhibitors, SEER Program, United States, Leukemia, Myelogenous, Chronic, BCR-ABL Positive mortality, Registries, Survival Rate trends
Abstract: Aim: To assess trends in survival and geographic disparities among children (0-14 years) with chronic myeloid leukaemia (CML) before and after the introduction of molecular therapy, namely tyrosine kinase inhibitors (TKIs) in Southern-Eastern European (SEE) countries and the USA., Methods: We calculated survival among children with CML, acute lymphoblastic (ALL) and acute myeloid leukaemia (AML) in 14 SEE (1990-2014) cancer registries and the U.S. Surveillance, Epidemiology and End Results Program (SEER, 1990-2012). We used Kaplan-Meier curves and multivariate Cox regression models to calculate hazard ratios (HRs) with 95% confidence intervals (CIs)., Results: Among 369 CML cases, substantial improvements were noted in 2-year survival during the post-TKI (range: 81-89%) compared to pre-TKI period (49-66%; HR: 0.37, 95% CI: 0.23-0.60). Risk of death was three times higher for <5-year-old children versus those aged 10-14 years (HR: 3.03, 95% CI: 1.85-4.94) and 56% higher for those living in SEE versus SEER (HR: 1.56, 95% CI: 1.01-2.42). Regardless of geographic area and period of TKI administration, however, age seems to be a significant determinant of CML prognosis (pre-TKI period, HR 0-4y : 2.71, 95% CI: 1.53-4.79; post-TKI period, HR 0-4y : 3.38, 95% CI: 1.29-8.85). Noticeably, post-TKI survival in CML overall approximates that for ALL, whereas therapeutic advancements for AML remain modest., Conclusion: Registry data show that introduction of molecular therapies coincides with revolutionised therapeutic outcomes in childhood CML entailing dramatically improved survival which is now similar to that in ALL. Given that age disparities in survival remain substantial, offering optimal therapy to entire populations is an urgent priority., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
Published: 2016
Full Text: View/download PDF

34. Incidence and time trends of childhood lymphomas: findings from 14 Southern and Eastern European cancer registries and the Surveillance, Epidemiology and End Results, USA.

Author: Georgakis MK, Karalexi MA, Agius D, Antunes L, Bastos J, Coza D, Demetriou A, Dimitrova N, Eser S, Florea M, Ryzhov A, Sekerija M, Žagar T, Zborovskaya A, Zivkovic S, Bouka E, Kanavidis P, Dana H, Hatzipantelis E, Kourti M, Moschovi M, Polychronopoulou S, Stiakaki E, Kantzanou Μ, Pourtsidis A, and Petridou ET
Subjects: Adolescent, Child, Child, Preschool, Europe epidemiology, Female, Humans, Incidence, Infant, Infant, Newborn, Male, Registries, SEER Program, United States epidemiology, Lymphoma epidemiology
Abstract: Purpose: To describe epidemiologic patterns of childhood (0-14 years) lymphomas in the Southern and Eastern European (SEE) region in comparison with the Surveillance, Epidemiology and End Results (SEER), USA, and explore tentative discrepancies., Methods: Childhood lymphomas were retrieved from 14 SEE registries (n = 4,702) and SEER (n = 4,416), diagnosed during 1990-2014; incidence rates were estimated and time trends were evaluated., Results: Overall age-adjusted incidence rate was higher in SEE (16.9/10 6 ) compared to SEER (13.6/10 6 ), because of a higher incidence of Hodgkin (HL, 7.5/10 6 vs. 5.1/10 6 ) and Burkitt lymphoma (BL, 3.1 vs. 2.3/10 6 ), whereas the incidence of non-Hodgkin lymphoma (NHL) was overall identical (5.9/10 6 vs. 5.8/10 6 ), albeit variable among SEE. Incidence increased with age, except for BL which peaked at 4 years; HL in SEE also showed an early male-specific peak at 4 years. The male preponderance was more pronounced for BL and attenuated with increasing age for HL. Increasing trends were noted in SEER for total lymphomas and NHL, and was marginal for HL, as contrasted to the decreasing HL and NHL trends generally observed in SEE registries, with the exception of increasing HL incidence in Portugal; of note, BL incidence trend followed a male-specific increasing trend in SEE., Conclusions: Registry-based data reveal variable patterns and time trends of childhood lymphomas in SEE and SEER during the last decades, possibly reflecting diverse levels of socioeconomic development of the populations in the respective areas; optimization of registration process may allow further exploration of molecular characteristics of disease subtypes.
Published: 2016
Full Text: View/download PDF

35. Disparities in melanoma incidence and mortality in South-Eastern Europe: Increasing incidence and divergent mortality patterns. Is progress around the corner?

Author: Barbaric J, Sekerija M, Agius D, Coza D, Dimitrova N, Demetriou A, Safaei Diba C, Eser S, Gavric Z, Primic-Zakelj M, Zivkovic S, Zvolsky M, Bray F, Coebergh JW, and Znaor A
Subjects: Adult, Age Distribution, Aged, Early Detection of Cancer, Europe epidemiology, Female, Health Services Accessibility, Humans, Incidence, Male, Melanoma diagnosis, Melanoma mortality, Melanoma prevention & control, Middle Aged, Mortality trends, Registries, Risk Factors, Sex Distribution, Skin Neoplasms diagnosis, Skin Neoplasms mortality, Skin Neoplasms prevention & control, Time Factors, Health Status Disparities, Healthcare Disparities trends, Melanoma epidemiology, Skin Neoplasms epidemiology
Abstract: Introduction: Most countries in South-Eastern Europe (SEE) have lower incidence, but higher mortality rates of malignant melanoma (MM) of the skin compared to North-Western Europe (NWE). We explored trends in MM incidence and mortality in SEE countries by sex and age and compared them with the trends in NWE., Methods: We obtained data on incident cases and deaths from MM (ICD-10 code C43) from 11 population-based cancer registries in Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Malta, Romania, Serbia, Slovakia, Slovenia and Turkey. We calculated age-specific rates for 25-49 ('young'), 50-69 ('middle aged') and 70+ years ('older') and estimated the average annual percent of change in incidence and mortality trends 2000-2010 according to age group and sex, using joinpoint regression analysis., Findings: The incidence rates of MM across the region were uniformly increasing. Significant increases in mortality rates were observed in middle aged men in Serbia and Bulgaria, middle aged women in Slovenia, older men in the Czech Republic, Serbia and Turkey, and older women in Slovenia and Serbia., Interpretation: While MM incidence rates were still increasing across SEE, mortality trends diverged and were less favourable than in NWE. Empowering cancer registration and improving the quality of incidence and mortality data will be essential for monitoring progress in MM control. In the context of prevention of melanoma, disparities in early detection appear to be widening the gap between SEE and NWE, while the provision of care to patients with advanced disease is likely to prove a challenge for regional healthcare budgets., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
Published: 2016
Full Text: View/download PDF

36. Childhood central nervous system tumour mortality and survival in Southern and Eastern Europe (1983-2014): Gaps persist across 14 cancer registries.

Author: Karalexi MA, Papathoma P, Thomopoulos TP, Ryzhov A, Zborovskaya A, Dimitrova N, Zivkovic S, Eser S, Antunes L, Sekerija M, Zagar T, Bastos J, Demetriou A, Agius D, Cozma R, Coza D, Bouka E, Dessypris N, Belechri M, Dana H, Hatzipantelis E, Papakonstantinou E, Polychronopoulou S, Pourtsidis A, Stiakaki E, Chatziioannou A, Manolitsi K, Orphanidis G, Papadopoulos S, Papathanasiou M, Patsouris E, Sgouros S, Zountsas B, Moschovi M, Steliarova-Foucher E, and Petridou ET
Subjects: Adolescent, Central Nervous System Neoplasms classification, Child, Child, Preschool, Europe epidemiology, Europe, Eastern epidemiology, Female, Follow-Up Studies, Geography, Humans, Infant, Male, Risk Factors, Rural Population statistics & numerical data, Survival Rate, Time Factors, Urban Population statistics & numerical data, Central Nervous System Neoplasms mortality, Mortality trends, Registries statistics & numerical data
Abstract: Aim: Childhood central nervous system (CNS) tumour registration and control programs in Southern and Eastern Europe remain thin, despite the lethal nature of the disease. Mortality/survival data were assembled to estimate the burden of malignant CNS tumours, as well as the potential role of sociodemographic survival determinants across 14 cancer registries of this region., Methods: Average age-adjusted mortality rates were calculated, whereas time trends were quantified through Poisson and Joinpoint regressions. Kaplan-Meier curves were derived for the maximum and the more recent (10 and 5 year) registration periods. Multivariate Cox regression models were used to assess demographic and disease-related determinants., Results: Variations in mortality (8-16 per million) and survival (5-year: 35-69%) were substantial among the participating registries; in most registries mortality trend was stable, whereas Bulgaria, having the highest starting rate, experienced decreasing annual mortality (-2.4%, p=0.001). A steep decrease in survival rates was evident before the second year of follow-up. After controlling for diagnostic subgroup, age, gender and diagnostic year, Greece seemed to present higher survival compared with the other contributing registries, although the follow-up period was short. Irrespective of country, however, rural residence was found to impose substantial adverse repercussions on survival (hazard ratio (HR): 1.2, 95% confidence interval (CI): 1.1-1.4)., Conclusion: Cross-country mortality and survival variations possibly reflect suboptimal levels of health care delivery and cancer control in some regions of Southern and Eastern Europe, notwithstanding questionable death certification patterns or follow-up procedures. Continuous childhood cancer registration and linkage with clinical data are prerequisite for the reduction of survival inequalities across Europe., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
Published: 2015
Full Text: View/download PDF

37. Childhood central nervous system tumours: Incidence and time trends in 13 Southern and Eastern European cancer registries.

Author: Papathoma P, Thomopoulos TP, Karalexi MA, Ryzhov A, Zborovskaya A, Dimitrova N, Zivkovic S, Eser S, Antunes L, Sekerija M, Zagar T, Bastos J, Demetriou A, Cozma R, Coza D, Bouka E, Dessypris N, Kantzanou M, Kanavidis P, Dana H, Hatzipantelis E, Moschovi M, Polychronopoulou S, Pourtsidis A, Stiakaki E, Papakonstantinou E, Oikonomou K, Sgouros S, Vakis A, Zountsas B, Bourgioti C, Kelekis N, Prassopoulos P, Choreftaki T, Papadopoulos S, Stefanaki K, Strantzia K, Cardis E, Steliarova-Foucher E, and Petridou ET
Subjects: Adolescent, Child, Child, Preschool, Europe epidemiology, Europe, Eastern epidemiology, Female, Humans, Incidence, Infant, Infant, Newborn, Male, Registries, Central Nervous System Neoplasms epidemiology
Abstract: Aim: Following completion of the first 5-year nationwide childhood (0-14 years) registration in Greece, central nervous system (CNS) tumour incidence rates are compared with those of 12 registries operating in 10 Southern-Eastern European countries., Methods: All CNS tumours, as defined by the International Classification of Childhood Cancer (ICCC-3) and registered in any period between 1983 and 2014 were collected from the collaborating cancer registries. Data were evaluated using standard International Agency for Research on Cancer (IARC) criteria. Crude and age-adjusted incidence rates (AIR) by age/gender/diagnostic subgroup were calculated, whereas time trends were assessed through Poisson and Joinpoint regression models., Results: 6062 CNS tumours were retrieved with non-malignant CNS tumours recorded in eight registries; therefore, the analyses were performed on 5191 malignant tumours. Proportion of death certificate only cases was low and morphologic verification overall high; yet five registries presented >10% unspecified neoplasms. The male/female ratio was 1.3 and incidence decreased gradually with age, apart from Turkey and Ukraine. Overall AIR for malignant tumours was 23/10(6) children, with the highest rates noted in Croatia and Serbia. A statistically significant AIR increase was noted in Bulgaria, whereas significant decreases were noted in Belarus, Croatia, Cyprus and Serbia. Although astrocytomas were overall the most common subgroup (30%) followed by embryonal tumours (26%), the latter was the predominant subgroup in six registries., Conclusion: Childhood cancer registration is expanding in Southern-Eastern Europe. The heterogeneity in registration practices and incidence patterns of CNS tumours necessitates further investigation aiming to provide clues in aetiology and direct investments into surveillance and early tumour detection., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
Published: 2015
Full Text: View/download PDF

38. Completeness and timeliness: Cancer registries could/should improve their performance.

Author: Zanetti R, Schmidtmann I, Sacchetto L, Binder-Foucard F, Bordoni A, Coza D, Ferretti S, Galceran J, Gavin A, Larranaga N, Robinson D, Tryggvadottir L, Van Eycken E, Zadnik V, Coebergh JW, and Rosso S
Subjects: Cause of Death, Data Collection, Death Certificates, Europe epidemiology, Humans, Incidence, Information Dissemination, Population Surveillance methods, Quality Improvement, Registries statistics & numerical data, Time Factors, Neoplasms epidemiology, Registries standards
Abstract: Unlabelled: Cancer registries must provide complete and reliable incidence information with the shortest possible delay for use in studies such as comparability, clustering, cancer in the elderly and adequacy of cancer surveillance. Methods of varying complexity are available to registries for monitoring completeness and timeliness. We wished to know which methods are currently in use among cancer registries, and to compare the results of our findings to those of a survey carried out in 2006., Methods: In the framework of the EUROCOURSE project, and to prepare cancer registries for participation in the ERA-net scheme, we launched a survey on the methods used to assess completeness, and also on the timeliness and methods of dissemination of results by registries. We sent the questionnaire to all general registries (GCRs) and specialised registries (SCRs) active in Europe and within the European Network of Cancer Registries (ENCR)., Results: With a response rate of 66% among GCRs and 59% among SCRs, we obtained data for analysis from 116 registries with a population coverage of ∼280 million. The most common methods used were comparison of trends (79%) and mortality/incidence ratios (more than 60%). More complex methods were used less commonly: capture-recapture by 30%, flow method by 18% and death certificate notification (DCN) methods with the Ajiki formula by 9%. The median latency for completion of ascertainment of incidence was 18 months. Additional time required for dissemination was of the order of 3-6 months, depending on the method: print or electronic. One fifth (21%) did not publish results for their own registry but only as a contribution to larger national or international data repositories and publications; this introduced a further delay in the availability of data., Conclusions: Cancer registries should improve the practice of measuring their completeness regularly and should move from traditional to more quantitative methods. This could also have implications in the timeliness of data publication., (Copyright © 2013 Elsevier Ltd. All rights reserved.)
Published: 2015
Full Text: View/download PDF

39. [Histopathological diagnostic concordance in bone and soft tissue sarcomas between two comprehensive cancer centers from eastern and western Europe: a collaborative experience].

Author: Somcutian O, Buiga R, Galatir M, Tudor Eniu D, Rachieru C, Coza D, and Terrier P
Subjects: Adolescent, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor analysis, Bone Neoplasms chemistry, Bone Neoplasms epidemiology, Child, Child, Preschool, Chondrosarcoma chemistry, Chondrosarcoma diagnosis, Chondrosarcoma epidemiology, Diagnosis, Differential, Diagnostic Errors, Female, France epidemiology, Humans, Incidence, Male, Middle Aged, Mitotic Index, Neoplasm Grading, Osteosarcoma chemistry, Osteosarcoma diagnosis, Osteosarcoma epidemiology, Reproducibility of Results, Retrospective Studies, Romania epidemiology, Sarcoma chemistry, Sarcoma epidemiology, Young Adult, Bone Neoplasms diagnosis, Cancer Care Facilities statistics & numerical data, Pathology Department, Hospital statistics & numerical data, Sarcoma diagnosis
Abstract: Introduction: This study aims to assess the degree of concordance of histological diagnosis of bone and soft tissue sarcomas between a Comprehensive Cancer Center (CCC) of Eastern Europe - not specialized in this area of pathology - and an important CCC of Western Europe, which is one of the coordinators of a clinical reference network in sarcoma pathology. The goal is to have an overview of the sarcomatous pathology in a region of Eastern Europe and to discover diagnostic discrepancies between the two centers, while determining their cause., Materials and Methods: The initial diagnosis was compared with the revised diagnosis on 110 specimens from 88 patients with bone or soft tissue sarcomas from East-European CCC, in a one-year period of time., Results: Complete diagnostic agreement was observed in 55 cases (62.5%), a partial agreement in 23 cases (26.1%) and a major disagreement in 10 cases (11.4%). Major discrepancies of the histological type was observed in only 3 cases (3.4%): one case of discordance benign/malignant and 2 cases of discordance mesenchymal/non mesenchymal. Minor histological discrepancies - not affecting the management of the patient - were observed in 18 cases (20.4%). A major discordance in grading - potentially changing the management of the patient - was noted in 7 cases (7.9%), and a minor discrepancy in 5 cases (5.7%)., Discussions: Some histological types were clearly overdiagnosed, like "adult fibrosarcomas" and "malignant peripheral nerve sheet tumors" (MPNST), mostly converted after the audit into "undifferentiated spindle cell sarcomas" or other types of sarcomas. Some "unclassified" sarcomas and "undifferentiated pleomorphic sarcomas" could be re-classified with the aid of an extensive panel of antibodies. Overall, immunohistochemistry was responsible, but not in exclusivity, for half of the minor discrepancies, and for 2 out of 3 cases of major histological discrepancies. Otherwise, the main cause of discrepancies was the difficulties in the interpretation of the morphology. Molecular biology was decisive in one case. Most grading discrepancies resulted from the appreciation of the mitotic index., Conclusions: The profile of the sarcomatous pathology in the northwest region of Romania does not appear to differ significantly from other parts of Europe or the world, but a prospective epidemiological study would be necessary to confirm this assessment. The expansion of immunohistochemical antibody panel, the over-specialization of pathologists and, in the future, the establishment of a national network of referral centers in sarcoma pathology, are required for a high level of histological diagnosis in Eastern Europe. A periodic external audit, continuing this trans-European collaboration between the two centers, would be beneficial for monitoring progress., (Copyright © 2014. Published by Elsevier Masson SAS.)
Published: 2015
Full Text: View/download PDF

40. Cancer incidence and mortality patterns in South Eastern Europe in the last decade: gaps persist compared with the rest of Europe.

Author: Znaor A, van den Hurk C, Primic-Zakelj M, Agius D, Coza D, Demetriou A, Dimitrova N, Eser S, Karakilinc H, Zivkovic S, Bray F, and Coebergh JW
Subjects: Breast Neoplasms epidemiology, Breast Neoplasms mortality, Colorectal Neoplasms epidemiology, Colorectal Neoplasms mortality, Europe epidemiology, Europe, Eastern epidemiology, Female, Humans, Incidence, Lung Neoplasms epidemiology, Lung Neoplasms mortality, Male, Neoplasms epidemiology, Prostatic Neoplasms epidemiology, Prostatic Neoplasms mortality, Regression Analysis, Survival Rate trends, Mortality trends, Neoplasms mortality, Registries statistics & numerical data
Abstract: Introduction: Cancer registration coverage and cancer control programmes in South Eastern (SE) Europe, embracing about six new EU member states, remain thin, despite a relatively high incidence and mortality burden from avoidable cancers, particularly in males. We assembled the most recent cancer registry data to estimate the burden of the 17 most common cancers in the region, from Slovenia to Cyprus and Malta., Methods: Data were made available for analysis from Bulgaria, Croatia, Cyprus, Malta, Romania (Cluj County), Serbia, Slovenia and Turkey (Antalya and Izmir provinces). We analysed incidence and mortality of the 17 most common cancers (counts and age-standardised rates, for the most recent year available and for the period 1999-2008). We used Joinpoint regression to quantify recent trends., Findings: For much of SE Europe, there were no marked declines in overall cancer mortality rates during 1999-2008. In men, lung cancer incidence and mortality rates were high compared to other European countries (age-standardised rates (ASRW) of incidence being 50-60/100,000 in most of the countries), and still increasing in Bulgaria, Serbia and Turkey. Prostate cancer incidence rapidly increased throughout the region by 3-12% annually, largely without any clear declines in mortality. Colorectal cancer incidence increased throughout the region, as did mortality especially in Croatia, Serbia and Bulgaria (average annual percentage change (AAPC) 1.5-2%). In women, breast cancer mortality significantly declined in Slovenia, Croatia and Malta (Average Annual Percentage of Change [AAPC] -2%, -1% and -5%, respectively), but not elsewhere. Cervical cancer incidence rates remained very high in Romania, Serbia and Bulgaria (ASRW>20/100,000)., Interpretation: Our data confirmed the North West to South East Europe gradient of increasing incidence and mortality rates of tobacco-related cancers, as well as increasing mortality rates of screen-detectable cancers. The lack of decline in overall cancer mortality also indicates suboptimal levels of cancer control in the region., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
Published: 2013
Full Text: View/download PDF

41. Cervical cancer assessment in Romania under EUROCHIP-2.

Author: Apostol I, Baban A, Nicula F, Suteu O, Coza D, Amati C, and Baili P
Subjects: Adult, Aged, Colposcopy statistics & numerical data, Early Detection of Cancer, European Union, Family Practice statistics & numerical data, Female, Gynecology statistics & numerical data, Humans, Incidence, Medical Oncology statistics & numerical data, Middle Aged, Romania epidemiology, Rural Population statistics & numerical data, Urban Population statistics & numerical data, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Neoplasms mortality, Uterine Cervical Neoplasms epidemiology, Uterine Cervical Neoplasms prevention & control
Abstract: Background: Inside the European project EUROCHIP-2, the Romania team has ruled out an assessment study regarding cervical cancer screening programs (CCS) in Romania, in Nov 2006-March 2007. The general purpose was to be aliened to European Council recommendations that states that an organized cervical screening program should be offered in all member states, in order to reduce the specific incidence and mortality. The aim of the study was to assess cervical cancer burden and current cervical cancer screening status in Romania and in various sub-regions (DR), and also to identify problems and barriers and to propose solutions for implementing an organized cervical cancer screening program at national level., Methods: The study was based on a statistical survey and a comprehensive literature review of the most important European, national and regional papers or studies completed in this field., Results: Over 2000-2006, a total number of 22,830 new cases and 12,763 deaths from cervical cancer was registered in Romania. In 2005, the crude rate of incidence varied largely in the 8 DR between 17.8-31.3 and mortality varied between 12.3-21.5. The proportion of women tested by DRs on total female population varied between 3.2%-0.6%; the highest screening activity was observed in region VI, where run the only organized CCS in Romania. In 2005, there were one GP per 578 female population aged 25-65; regarding the specialists in 2007 per country we had: 3,012 women aged 25-65 per one gynecologist, 21,195 women per one oncologist and 13,258 women per one histopathologist., Discussion and Conclusion: There were no major changes in policy screening over 2000-2006 correlated with no major difference in specific mortality in Romania. Significant differences in incidence and mortality between DRs were observed in 2005, which impose deeper analyzes of local conditions and resources and local strategies to be adopted. The burden of cervical cancer is particularly high in Romania and is related to the absence of an organized CCS program or the ineffectiveness of the opportunistic screening programs. It is needed that European Council recommendations be implemented and quality assurance strategies to be checked and maintained at all screening levels in Romania.
Published: 2010
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

41 results on '"D. Coza"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources